Any corticosteroid therapy for indications other than GVHD at doses > 1 mg/kg per day methylprednisolone (or prednisone equivalent) within 7 days of randomization.Xx_NEWLINE_xXChronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)Xx_NEWLINE_xXNo patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 7 days of randomization; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients must not have received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to registration; inhaled or topical steroids, and adrenal replacement doses =< 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients with resected or irradiated brain metastases or those treated with stereotactic radiation therapy are eligible to enroll, provided that they do not require treatment with steroids that exceeds 10 mg of prednisone daily or equivalentXx_NEWLINE_xXNo ongoing therapy with corticosteroids greater than 10 mg of prednisone or its equivalent per day; please note: inhaled and topical steroids are permittedXx_NEWLINE_xXPatients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatmentXx_NEWLINE_xXKnown autoimmune disease requiring active treatment; subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of registration are excluded; inhaled or topical steroids, and adrenal replacement steroid doses =< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatient requires systemic, pharmacologic doses of corticosteroids (equivalent to >30 mg hydrocortisone/day) Note: Replacement doses (equivalent to ? 5 mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as neededXx_NEWLINE_xXChronic use, as defined by > 2 weeks of a corticosteroid agent that is >= 20 mg/day of prednisone or its equivalent, within 4 weeks prior to first administration of BIXx_NEWLINE_xXRequirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic solutionXx_NEWLINE_xXParticipants who received greater than 10 days of corticosteroids in the preceding 30 days prior to enrollment; physiologic dosing of steroid is 4-5 mg/m^2/day prednisone, 0.03-0.15 mg/kg/day dexamethasone, or 0.5-0.75 mg/kg/day hydrocortisone; contact the AMC Protocol Team for physiologic dosing limits for other corticosteroidsXx_NEWLINE_xXReceive dexamethasone equivalent dose </=2 mg per day, stable or decreased for >/= three days prior to Day 0;Xx_NEWLINE_xXDexamethasone equivalent dose >2 mg per day;Xx_NEWLINE_xXSubjects requiring systemic steroid therapy should be receiving ? 10 mg/day of prednisone (or equivalent) for the 2 weeks preceding start of study.Xx_NEWLINE_xXDaily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate, or extracorporeal photopheresisXx_NEWLINE_xXOngoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids > 20 mg of prednisone (or equivalent) once daily (QD)Xx_NEWLINE_xXSystemic steroid therapy (>10 mg daily prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment (Note: topical, inhaled, nasal and ophthalmic steroids are not prohibited).Xx_NEWLINE_xXRecent corticosteroid therapy at a cumulative dose equivalent to >= 140 mg of prednisone or a single dose equivalent to >= 40 mg of dexamethasone within 2 weeks prior the first dose of study drug.Xx_NEWLINE_xXRequires treatment with high dose systemic corticosteroids defined as dexamethasone > 2 mg/day or bioequivalent within at least 7 days of initiating therapyXx_NEWLINE_xXSubjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ? 10 mg prednisone daily). Note: Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be ?10 mg per day of prednisone or equivalent.Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization (unless used to treat investigational drug-related adverse events); inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xX< 4 mg dexamethasone daily (or equivalent if on another corticosteroid) at time of start of therapy; patients on a steroid taper post-surgery and are anticipated to be on < 4 mg at time of chemoradiation initiation will be eligible to consent but to initiate treatment on trial, the participant must be on < 4 mg or equivalent of steroids otherwise participate will be deemed a screen fail and be replacedXx_NEWLINE_xXIs receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\r\n* Physiologic doses of steroids (e.g. =< 10 mg prednisone/day or equivalent) are allowed; topical, inhaled, nasal and ophthalmic steroids are allowedXx_NEWLINE_xXTreatment with systemic corticosteroids >20 mg/day, prednisone or equivalentXx_NEWLINE_xXChronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310Xx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration; exceptions are:\r\n* Inhaled or topical steroids and\r\n* Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of active autoimmune diseaseXx_NEWLINE_xXOngoing chronic systemic steroid therapy required (>10 mg oral prednisone daily or equivalent)Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeksXx_NEWLINE_xXPatients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids in the setting of adrenal insufficiency or treatment with low, stable dose of steroid (<10mg/ day prednisone or equivalent) for stable CNS metastatic disease.Xx_NEWLINE_xXRequires treatment with high dose systemic corticosteroids defined as dexamethasone > 2 mg/day or bioequivalent within 7 days of initiating therapyXx_NEWLINE_xXSubject currently using or have received immunosuppressive medications within 14 days prior to the first dose of KHK2455, with the exception of topical or systemic corticosteroids that are not to exceed 10 mg/day of prednisone or equivalent;Xx_NEWLINE_xXSubject with Graft vs. Host Disease (GVHD) who is receiving treatment with systemic glucocorticoids > 10 mg/day equivalent of prednisone; however, treatment with low dose glucocorticoids (? 10 mg/day equivalent of prednisone) is permittedXx_NEWLINE_xXThe use of systemic glucocorticoids in excess of 10 mg/day equivalent of prednisone is permitted provided it is not for the treatment of GVHD (e.g. chronic obstructive pulmonary disease, anti-emetic, infusion reactions). The chronic use of topical, inhaled, and locally injected steroids is permittedXx_NEWLINE_xXPhysiologic doses of corticosteroids are permitted (i.e., no more than 10 mg of prednisone daily)Xx_NEWLINE_xXPatients requiring chronic high dose immunosuppressants including steroids (prednisone daily equivalent of >= 10 mg)Xx_NEWLINE_xXPrior treated brain or meningeal metastases must be without evidence of progression (confirmed by MRI) for at least 8 weeks and off immunosuppressive doses of systemic steroids (greater than 10 mg/day prednisone or equivalent) for at least 4 weeks before study drug administrationXx_NEWLINE_xXImmunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses greater than 7.5 to 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administration.Xx_NEWLINE_xXDaily requirement for corticosteroids (> 10 mg prednisone once daily [QD] or equivalent)Xx_NEWLINE_xXAny immunomodulatory drug therapy, anti-neoplastic hormonal therapy (unless dose has been stable for 3 months prior to Baseline and will remain stable during the trial), immunosuppressive therapy, corticosteroids >20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.Xx_NEWLINE_xXAny prednisone (or equivalent corticosteroids) use within 2 weeks of study entryXx_NEWLINE_xXOn chronic systemic steroid therapy (>10 mg/day prednisone or equivalent) within 2 weeks prior to first dose of study drug or on any other form of immunosuppressive medicationXx_NEWLINE_xXParticipants must have steroid refractory cGVHD, defined as having persistent signs and symptoms of chronic GVHD despite the use of prednisone at >= 0. 5 mg/kg/day (or equivalent) for at least 4 weeks; patients may remain on steroids while enrolled in the studyXx_NEWLINE_xXFOR THE PHASE II PORTION OF THE STUDY: Steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms; patients with either extensive chronic GVHD or limited chronic GVHD requiring systemic therapy are eligibleXx_NEWLINE_xXOngoing prednisone requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXUse of systemic corticosteroids >0.5 mg/kg/day within 10 days prior to obtaining 200 mL whole blood starting material.Xx_NEWLINE_xXCumulative dose of doxorubicin or equivalent of > 360 mg/m^2 during prior adjuvant therapyXx_NEWLINE_xXTreatment with high dose systemic corticosteroids defined as dexamethasone > 2 mg/day or bioequivalent within 7 days of initiating therapyXx_NEWLINE_xXParticipants taking corticosteroids (>= 10 mg of prednisone or equivalent). Exceptions may be discussed with the overall principal investigator (PI) on a case by case basisXx_NEWLINE_xXParticipants with a condition requiring systemic treatment with corticosteroids of > 10 mg daily prednisone (or equivalent), or subjects requiring other immunosuppressive medications within 14 days of first treatment. Inhaled, topical, ophthalmologic, local steroid injections, and adrenal replacement steroid > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent systemic steroid therapy other than physiologic replacement (i.e. prednisone ? 10 mg or equivalent). Inhaled or topical steroid use is allowed.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses (the equivalent of prednisone ?10 mg/day is acceptable), or on any other form of immunosuppressive medication.Xx_NEWLINE_xXExisting significant autoimmune conditions; patients with a history of Hashimoto thyroiditis who are stable on replacement hormone therapy are not excluded; patients cannot be on long-term (> 4 weeks) corticosteroids at doses exceeding prednisone 20 mg (or its equivalent) prior to enrollment; short-term corticosteroid dosing is permitted as long as steroids are discontinued within 2 weeks of study enrollmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment or is taking chronic systemic steroids (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of trial treatment; Note: Subjects with asthma or chronic obstructive pulmonary disease that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are not excluded from the studyXx_NEWLINE_xXSubjects receiving immunologically based treatment for any reason, including chronic steroids or prednisone (at dose > 10 mg/day of prednisone) within 14 day prior to first study treatment; inhaled or topical steroids or systemic steroids (at dose =< 10 mg/day of prednisone) is permittedXx_NEWLINE_xXEvidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollment; (steroids for pre-medication for imaging studies are allowed).Xx_NEWLINE_xXTreatment with systemic corticosteroids ? 20 mg/day prednisone or equivalent, for non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable dose for at least 4 weeks prior to Day 1 of Cycle 1 is required.Xx_NEWLINE_xXParticipants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXMust not have required immunosuppressive agents, other than corticosteroids for the management of an adverse event and not currently requite maintenance doses of >10 milligrams (mg) prednisone (or equivalent) per day.Xx_NEWLINE_xXIs on chronic systemic steroid therapy in excess of replacement doses (prednisone ? 10 mg/day is acceptable), or on any other form of immunosuppressive medication. For CTCL, continued use of either prednisone ?10 mg/day or continued use of topical steroids is acceptable.Xx_NEWLINE_xXAny other concurrent investigational agent or chemotherapy, radiotherapy, immunotherapy, or corticosteroids (prednisone up to 20 mg/day or its equivalent is permitted for chronic conditions)Xx_NEWLINE_xXA lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1 week, ORXx_NEWLINE_xXDisease persistence without improvement despite continued treatment with prednisone at > 0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks, ORXx_NEWLINE_xXAny corticosteroid therapy for indications other than cGvHD at doses > 1 mg/kg/day methylprednisolone or equivalent within 7 days of Cycle 1 Day 1Xx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than equivalent of 5 mg prednisone/prednisolone once dailyXx_NEWLINE_xXNeed of more than 10 mg/day of prednisone or an equivalent dose of other anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to treat a chronic disease (e.g., rheumatic disorder)Xx_NEWLINE_xXNo requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomizationXx_NEWLINE_xXThe patient must be either off systemic steroids or be on stable dose of dexamethasone (max 0.1 mg/kg/day; maximum 4mg/day) at time of enrollmentXx_NEWLINE_xXEXCLUSION - INFUSION: Current use of systemic corticosteroids > 0.5 mg/kg/dayXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of uncontrolled autoimmune diseaseXx_NEWLINE_xXSystemic glucocorticoid therapy (prednisone >10 mg/day orally or equivalent) within the last 4 weeks prior to first dose, unless tapered and on a stable dose (prednisone ?10 mg/day orally or equivalent) for at least 1 week.Xx_NEWLINE_xXTREATMENT EXCLUSION: Current use of systemic corticosteroids at a dose equivalent to 0.5 mg/kg/day of prednisone or higherXx_NEWLINE_xXImmunosuppressive steroids within 3 months before first ZW25 dosing, except for chronic steroid doses of ?15 mg per day for adrenal insufficiencyXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatient receives chronic steroid use > 10 mg prednisone (or steroid equivalent) dailyXx_NEWLINE_xXCorticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXUse of systemic corticosteroids > 0.5 mg/kg/day prednisolone or equivalent does of alternative corticosteroid within 10 days prior to obtaining 200 mL starting materialXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permittedXx_NEWLINE_xXPatients who are receiving additional immunosuppressive therapy or any steroids (except concurrent corticosteroid usage if no more than 20 mg per day, prednisolone equivalent is applied)Xx_NEWLINE_xXDoses ? 10 mg/kg/day prednisolone or equivalent is allowed, provided that the steroid dose has been stable or tapering for at least 14 days prior to the first dose of CUDC-907.Xx_NEWLINE_xXPatient may not have received prior systemic chemotherapy for LCH or other malignant disorder; systemic steroids equivalent to prednisone 1 mg/kg/day cannot have been given for more than 7 days in the 30 day period prior to study enrollment; however, patients who have only received surgical or radiation therapy, intralesional injection of steroids, or topical steroids may be enrolledXx_NEWLINE_xXPatients requiring systemic steroid therapy or any immunosuppressive therapy (?10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days prior to first dose of study treatment.Xx_NEWLINE_xXConcomitant corticosteroids unless patient has been on a stable dose of prednisone (or equivalent) of =< 10 mg daily for at least 2 weeks prior to first dose of study drugXx_NEWLINE_xXReceiving steroids > the equivalent of 10 mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritisXx_NEWLINE_xXCurrently taking corticosteroids (> 0.5 mg/kg/day prednisone or equivalent)Xx_NEWLINE_xXCurrently taking corticosteroids (> 0.5 mg/kg/day prednisone or equivalent)Xx_NEWLINE_xXSubjects who received any corticosteroid therapy (for non-GVHD) at doses >0.5 mg/kg/day prednisone (or equivalent) within 7 days prior to the onset of GVHD therapy.Xx_NEWLINE_xXPatients may not be receiving systemic corticosteroid therapy at a prednisone dose > 20 mg/day (or steroid equivalent) within 2 weeks of starting study.Xx_NEWLINE_xXMust have one of the following diagnoses:\r\n* Acute GVHD (grade II-IV) requiring systemic therapy and refractory/unresponsive to glucocorticoid (>= 1 mg prednisone-equivalent/kg x 1 week)\r\n* Chronic GVHD that is extensive and not improved despite therapy with glucocorticoid (>= 0.5 mg prednisone-equivalent/kg/day) and therapeutic doses of a calcineurin inhibitor for at least 4 weeks, or worsened within 2 weeks, or overlap syndrome not responding to glucocorticoid treatment (>= 1 mg prednisone-equivalent/kg x 1 week)Xx_NEWLINE_xXEXCLUSION CRITERIA FOR STRATUM C: Patients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as =< 0.75 mg/m^2/day dexamethasone equivalent) at time of enrollment; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the studyXx_NEWLINE_xXPreviously untreated; NOTE: this includes any chemotherapy or immunotherapy or RIT; patients who received corticosteroids for diseases other than lymphoma are eligible as long as prednisone dose is =< 10 mg/dayXx_NEWLINE_xXCorticosteroid therapy at the time the patient enters the protocol; NOTE: patients using prednisone or its equivalent for adrenal failure or using =< 10mg of prednisone/day for other benign causes are acceptedXx_NEWLINE_xXMust be on =< 20 mg of oral daily prednisone or equivalent for GVHDXx_NEWLINE_xXPatients with moderate or severe chronic graft-versus host requiring more than 20 mg of oral prednisone or equivalent therapy are excluded from the studyXx_NEWLINE_xXDaily dexamethasone > 4 mg at the time of registrationXx_NEWLINE_xXCurrent use of systemic corticosteroids > 0.5 mg/kg/dayXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatmentXx_NEWLINE_xXSystemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of study drug administration are prohibitedXx_NEWLINE_xXCurrently taking corticosteroids (> 0.5 mg/kg/day prednisone or equivalent) for therapy of GVHDXx_NEWLINE_xXSystemic steroids that have not been stabilized to the equivalent of =< 10 mg/day prednisone prior to the start of the study drugsXx_NEWLINE_xXCumulative doxorubicin dose >= 400 mg/m^2 (> 450 mg/m^2 for malignant soft tissue and bone tumor patients) or cumulative epirubicin dose >= 800 mg/m^2Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg/day prednisone or equivalent daily) or other immunosuppressive medications within 14 days prior to initiating protocol-indicated treatment.\r\n* In the absence of active autoimmune disease: Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, ocular, intra-articular, intranasal, and inhalational) =< 10 mg/day prednisone or equivalent daily; and physiologic replacement doses of systemic corticosteroids =< 10 mg/day prednisone or equivalent daily (e.g. hormone replacement therapy needed in patients with hypophysitis).Xx_NEWLINE_xXTREATMENT WITH SJCAR19: Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CAR T-cell infusionXx_NEWLINE_xXPrior treated CNS metastases must be without MRI evidence of recurrence for at least 4 weeks after treatment; patients must be off immunosuppressive doses of systemic steroids (>= 10 mg/day prednisone or equivalent) for at least 14 days prior to study drug administration, and must have returned to neurologic baseline status postoperatively\r\n* The 4-week period of stability is measured after the completion of the neurologic interventions (ie, surgery and/or radiation)Xx_NEWLINE_xXIn addition to neurosurgery to treat CNS metastases, adjuvant radiation after the resection of CNS metastasis is allowed; immunosuppressive doses of systemic steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 14 days before study drug administrationXx_NEWLINE_xXIf patient has known brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of ?10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).Xx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent: a. subjects with type I diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible b. subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses 10 mg of prednisone or equivalent per day.Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of study administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg/day prednisone equivalents are permitted in the absence of autoimmune diseaseXx_NEWLINE_xXHistory of any condition requiring anti-platelet therapy (aspirin > 300 mg/day, clopidogrel > 75 mg/day)Xx_NEWLINE_xXCorticosteroids use exceeding a cumulative dose of 160 mg of dexamethasone during screeningXx_NEWLINE_xXImmunosuppressive treatments within 4 weeks prior to embolization, unless prednisone ? 5 mg or equivalentXx_NEWLINE_xXChronic use of corticosteroids in excess of prednisone 20 mg/day or its equivalentXx_NEWLINE_xXPatients that require decadron > 4 mg/ day or equivalent of steroids.Xx_NEWLINE_xXChronic steroid therapy, however prednisone or its equivalent is allowed at =< 10 mg/day.Xx_NEWLINE_xXPatients may be on steroids prior to initiation of treatment, provided that, by cycle 1 day 1, steroid use is tapered down to less than or equal to 10 mg/day of prednisoneXx_NEWLINE_xXRequire systemic pharmacologic doses of corticosteroids greater than the equivalent of 10 mg/day prednisone; topical, ophthalmologic and inhalational steroids are permitted. Subjects who have a history of adrenal insufficiency and are receiving greater than 10 mg/day prednisone may be eligible but only after Sponsor consultations. Subjects who are currently receiving steroids at a dose of ? 10 mg/day do not need to discontinue steroids prior to enrollmentXx_NEWLINE_xXThe subject is off corticosteroids of > 10 mg/day prednisone or equivalent.Xx_NEWLINE_xXPre-existing condition that warrants long-term corticosteroid use in excess of 10 mg prednisone/prednisolone daily. (Note: If a subject has been receiving glucocorticoids other than prednisone or prednisolone, it will be necessary to switch the glucocorticoids to prednisone or prednisolone 5 mg twice daily prior to day 1)Xx_NEWLINE_xXParticipants must not have a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of > 10 mg prednisone daily or equivalent at time of first dose of trial treatmentXx_NEWLINE_xXSteroid doses greater than an equivalent of prednisone 10 mg dailyXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment; inhaled or topical steroids, and adrenal replacement steroid 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXEvidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment; however, in the setting of non-immune mediated indications for steroid use, chronic/active low dose steroid use may be permitted at the discretion of the principal investigator; the dose of steroid allowed in this setting is also at the discretion of the principal investigator; (use of inhaled or topical steroids is permitted)Xx_NEWLINE_xXNo concurrent treatment for the CNS disease (e.g. surgery, radiation, corticosteroids >10 mg prednisone/day or equivalent)Xx_NEWLINE_xXTreatment with systemic corticosteroids (> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 2 weeksXx_NEWLINE_xXCurrent immunosuppressive therapy including > 10 mg/day of prednisone within 14 days of enrollment is not permitted; inhaled or topical steroids, and adrenal replacement steroid doses =< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXReceived a cumulative dose of corticosteroids equivalent to greater than or equal to ( >=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drugXx_NEWLINE_xXResearch participant must not require more than 2 mg three times daily TID of dexamethasone on the day of PBMC collection.Xx_NEWLINE_xXIf patient is currently on prednisone or other corticosteroids for palliation, the dose must be less than or equal to 10 mg a day or its equivalent dose and it must have been started at least 4 weeks prior to cycle 1 day 1Xx_NEWLINE_xXSystemic therapy with corticosteroids at >20 mg/day prednisone or equivalent within 1 week prior to the first dose of study drugXx_NEWLINE_xXSubjects with immunotherapy related adverse events requiring high doses of steroids (? 40 mg/day of prednisone) are not eligible.Xx_NEWLINE_xXInability to begin a prednisone dose ?0.5 mg/kg/d for the treatment of cGVHDXx_NEWLINE_xXPhase I patients must not be receiving greater than 1 mg dexamethasone/day (or an equivalent amount of an alternative corticosteroid) for at least 1 week prior to treatment startXx_NEWLINE_xXSystemic corticosteroid therapy at doses of greater than 5 mg daily for therapeutic and not adrenal replacement indications (maintenance steroid use for adrenal insufficiency is permitted)Xx_NEWLINE_xXRegular use of immunosuppressant drugs such as steroids (> 15 mg prednisone equivalents), azathioprine, tacrolimus, cyclosporine, etc; use is not permitted within 4 weeks before recruitmentXx_NEWLINE_xXHave Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 on stable or reducing dose of steroids for symptom management (not more than 8 mg of dexamethasone or equivalent per day) for 5 days prior to enrollment; change in glucocorticoid dose for any purpose other than to modulate symptoms from an adverse event; Note: The use of physiologic doses (e.g., prednisone 10 mg) of corticosteroids may be approved after consultation with Merck & Co; use of prophylactic corticosteroids to avoid allergic reactions (e.g. IV contrast dye) is permittedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy prior to trial treatment; patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (> 10 mg prednisone daily or equivalent)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients who require anticoagulation or systemic steroids at doses >10 mg daily of prednisone or equivalent or any immunosuppressive drugs. Beta-blocker therapy, while not exclusionary, is discouraged and alternatives should be sought if possible. The beta-blocker might compromise use of epinephrine for the rare possibility of anaphylaxis.Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune diseaseXx_NEWLINE_xXAny condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug; inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXThe following medications are prohibited within 2 weeks of enrollment and while on study drug:\r\n* 5 alpha-reductase inhibitors (finasteride, dutasteride)\r\n* Biologic or other agents with anti-tumor activity against prostate cancer (excluding herbal supplements)\r\n* Systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone\r\n** Premedication with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone is permitted prior to docetaxel infusions\r\n* Androgens (testosterone, dehydroepiandrosterone [DHEA], etc.)Xx_NEWLINE_xXPatients with evidence of clinically significant immunosuppression such as the following are ineligible:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollmentXx_NEWLINE_xXPatients on corticosteroids > 0.1 mg/Kg/day (i.e. > the maximum dose of 4mg/day)Xx_NEWLINE_xXSubject is receiving systemic steroids at doses greater than the equivalent of prednisone 10 mg daily, with the exception of intermittent use for the treatment of emesisXx_NEWLINE_xXConcomitant use of systemic corticosteroids at physiologic doses or > 10 mg/day of prednisone or equivalentXx_NEWLINE_xXReceiving systemic steroid therapy of > 10 mg prednisone daily or equivalent\r\n* Note:\r\n** Corticosteroid use on study after cycle 1 for management of adverse events, serious adverse events, and events of clinical interest, as a premedication for IV contrast allergies/reactions, or if considered necessary for a subject’s welfare is\r\nallowed\r\n** Subjects who receive daily steroid replacement therapy are an exception; daily prednisone at doses of 5 to 7.5 mg is an example of replacement therapy\r\n** Equivalent hydrocortisone doses are also permitted if administered as replacement therapyXx_NEWLINE_xXNeed for current chronic corticosteroid therapy (>= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)Xx_NEWLINE_xXRequirement for corticosteroids greater than the equivalent of 10 mg of prednisone daily for more than 2 weeks.Xx_NEWLINE_xXPatients requiring corticosteroid therapy at a dose of 15 mg or more per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptableXx_NEWLINE_xXPatients must require no corticosteroid therapy or dose of less than 15 mg per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptable until the day before the start of lymphodepletionXx_NEWLINE_xXThe treating physician expects that the patient will not require more than physiologic replacement dose of steroids defined as 32 mg of cortisone per day or its equivalentXx_NEWLINE_xXDexamethasone dose =< 4 mg dailyXx_NEWLINE_xXSubjects who are currently using more than 5mg/day of prednisone (or an equivalent glucocorticoid exceeding physiologic replacement levels)Xx_NEWLINE_xXPatients who take any immune or bone marrow suppressive agents including any systemic corticosteroid that exceed an equivalent of 10 mg prednisone per day within 2 weeks from the study treatment. Inhalation or topical steroids are allowed.Xx_NEWLINE_xXMedical history of autoimmune disease (e.g. Crohn’s disease, ulcerative colitis) or other disease requiring systemic glucocorticoid or immunosuppressive therapy; subjects who receive daily steroid replacement therapy serve as an exception to this rule; daily prednisone equivalent at doses up to 10 mg would qualifyXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXLong term or concurrent use of corticosteroid therapy other than for premedication or supportive care use as detailed in the protocol; physiologic doses of steroids (e.g. equivalent to or less than oral prednisone 10 mg daily) are allowed and do not require approvalXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of > 10 mg prednisone daily or equivalent at time of first dose of trial treatmentXx_NEWLINE_xXPatients who are on high dose steroid (e.g. > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)Xx_NEWLINE_xXOff all but replacement dose of corticosteroids from Day -7 to Day 28 (replacement dose is the patient's individualized dose defined for physiological replacement).Xx_NEWLINE_xXPatients may not receive ? 20 mg of prednisone or equivalent between days -7 and +28 of UCART123 infusion. Hydrocortisone required for mineralocorticoid replacement therapy is authorized at all times as needed clinically. Topical, inhaled, or nasal route of steroids are permitted;Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of > 10 mg prednisone daily or equivalent at time of first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapy if greater than the equivalent of 5 mg prednisone orally (PO) daily; patients previously on steroids must be off steroids for four weeks prior to treatmentXx_NEWLINE_xXCorticosteroids will be allowed at enrollment and during the first month of treatment with T-DM1 after SRS, up to a dose of no more than 10 mg of dexamethasone daily or equivalent; patients that need to continue corticosteroids after the initial month will be allowed to continue in the protocol treatment if no further increase in dose is necessary; patients that need increase in dose of corticosteroid after initial month will be taken off protocol treatmentXx_NEWLINE_xXOff all but replacement dose of corticosteroids from Day -7 to Day 28 (replacement dose is the patient's individualized dose defined for physiological replacement).Xx_NEWLINE_xXPatients may not receive ? 20 mg of prednisone or equivalent between days -7 and +28 of UCART123 infusion. Hydrocortisone required for mineralocorticoid replacement therapy is authorized at all times as needed clinically. Topical, inhaled, or nasal route of steroids are permitted;Xx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.)Xx_NEWLINE_xXPrior and concomitant therapy:\r\n* Prior exposure to any PI3 kinase inhibitor\r\n* Exposure to chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to entering the study or lack of recovery from adverse events due to previously administered treatments\r\n* Ongoing chronic pharmacologic immunosuppression, e.g. cyclosporine, or systemic steroids that have not been stabilized to the equivalent of =< 10 mg/day prednisone prior to the start of the study drug\r\n* Other concurrent investigational agents during the study periodXx_NEWLINE_xXThe patient must not be on a corticosteroid dose greater than physiologic replacement dosing defined as 30 mg of cortisone per day or its equivalentXx_NEWLINE_xXChronic steroid dependency (prednisone equivalent > 10 mg/day); any steroid use should be discontinued at least 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXPatients with treated supratentorial metastases are allowed if stable, the patient is off steroids or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent) and no evidence of intracranial hemorrhageXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization; inhaled or topical steroids and adrenal replacement steroid doses > 10mg daily prednisone equivalent, are permitted in the absence of uncontrolled autoimmune diseaseXx_NEWLINE_xXReceived a cumulative dose of corticosteroids equivalent to greater than or equal to (>=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drugXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed; patients may be using topical or inhaled corticosteroids; previous corticosteroid therapy must be stopped or reduced to the allowed dose at least 7 days prior to the first study drug administration; if a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the consent documentXx_NEWLINE_xXReceiving corticosteroids at > 20 mg (age > 17) or > 0.5 mg/kg (age < 18) daily prednisone dose or equivalent.Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent autoimmune disease requiring >= 20 mg/day of prednisone or systemic immunosuppressive therapy (eg. with cyclosporine or azathioprine).Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of registration; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXEvidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* HIV positive \r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollment\r\n* Concurrent opportunistic infectionXx_NEWLINE_xXEvidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment; however, in the setting of non-immune mediated indications for use, chronic/active low dose steroid use may be permitted at the discretion of the principal investigatorXx_NEWLINE_xXNot currently requiring systemic corticosteroid therapy (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) or any other immune suppressive medicationsXx_NEWLINE_xXSubject has received a cumulative dose of corticosteroids more than the equivalent of >= 140 mg of prednisone within the 2 week period before cycle 1, day 1Xx_NEWLINE_xXPatients must not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for 14 days before apheresis and CAR T-cell infusion; patients must also not take corticosteroids at doses higher than 5 mg/day of prednisone or equivalent at any time after the CAR T cell infusionXx_NEWLINE_xXCorticosteroid use =< 2 weeks prior to registration; NOTE: patients must be off corticosteroids for at least 2 weeks prior to registration; this includes oral, IV, subcutaneous, or inhaled route of administration; patients on chronic corticosteroid for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)Xx_NEWLINE_xXSubject using chronic systemic steroids greater than the equivalent of 10 mg of prednisone/prednisolone per day in the 2 weeks preceding study entry; replacement doses of steroids, topical, inhalational, nasal and ophthalmic steroids are permittedXx_NEWLINE_xXNo use of systemic steroids greater than the equivalent of 10 mg of prednisone/prednisolone per day within 4 weeks prior to enrollmentXx_NEWLINE_xXCorticosteroid use >30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom controlXx_NEWLINE_xXHistory of syndrome or medical condition(s) that requires systemic steroids (> 10 mg daily prednisone equivalents) or immunosuppressive medications.Xx_NEWLINE_xXSubjects requiring escalating or chronic supraphysiologic doses of corticosteroids (> 10 mg/d of prednisone equivalent) for control of disease at the time of registrationXx_NEWLINE_xXTherapeutic doses of corticosteroids (defined as >20 mg/day prednisone or equivalent) within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, and inhaled steroids are permitted.Xx_NEWLINE_xXAt least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted).Xx_NEWLINE_xXPatients with treated, non-progressive brain metastases, off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.Xx_NEWLINE_xXPrednisone dose =< 5 mg/day and off all other systemic immunosuppressive medications for at least 4 weeks prior to study entryXx_NEWLINE_xXAny condition requiring treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of the first dose of study drug; inhaled, topical, ocular or intra-articular steroids and adrenal replacement steroid doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCorticosteroid therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drugXx_NEWLINE_xXRequires treatment with high dose systemic corticosteroids defined as dexamethasone > 4 mg/day or bioequivalent for at least 3 consecutive days within 2 weeks of registrationXx_NEWLINE_xXImmunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810Xx_NEWLINE_xXDexamethasone dose should be =< 4 mg/day or steroid equivalent prior to starting treatment; if higher doses are needed, consult with study chairXx_NEWLINE_xXCELL PROCUREMENT: Prior to procurement current use of systemic corticosteroids at doses >= 10mg/day prednisone or its equivalent; those receiving < 10mg/day may be enrolled at discretion of investigator; (Note: corticosteroid use with doses at the discretion of the treating physician are allowed after procurement up to the beginning of lymphodepletion; corticosteroid use is contraindicated following iC9-CAR19 infusion unless medically necessary e.g., to treat CRS)\r\n* Physiologic replacement with hydrocortisone is allowed at doses 6-12 mg/m^2/day, or equivalentXx_NEWLINE_xXLYMPHODEPLETION: Use of systemic corticosteroids at doses >= 10mg/day prednisone or its equivalent; those receiving < 10mg/day may be enrolled at discretion of investigator; (Note: Corticosteroid use with doses at the discretion of the treating physician are allowed after procurement up to the beginning of lymphodepletion)\r\n* Physiologic replacement with hydrocortisone is allowed at 6-12 mg/m2/day, or equivalentXx_NEWLINE_xXPatients who have had prior everolimus but were not able to tolerate a 10 mg daily doseXx_NEWLINE_xXChronic use of corticosteroids in excess of prednisone 30 mg/day or its equivalentXx_NEWLINE_xXParticipants must have steroid-refractory cGVHD, which is defined as having persistent signs and symptoms of cGVHD despite the use of prednisone at 0.20 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptomsXx_NEWLINE_xXPatients should not have any uncontrolled illness including ongoing or active infection; patients with an ongoing prednisone requirement of > 1 mg/kg/day (or equivalent) will be excludedXx_NEWLINE_xXPatients requiring chronic systemic immunosuppressants, including steroids (prednisone daily equivalent of >10 mg).Xx_NEWLINE_xXBrain metastases that are clinically unstable (e.g. showing unequivocal growth on imaging, requiring radiation therapy, or steroids >10mg of prednisone equivalent) within 4 weeks of first dose of study drug.Xx_NEWLINE_xXAdministration of or condition requiring administration of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating study treatment; Exception: patients with conditions that can be managed with steroids equivalent to or less than an oral prednisone dose of 10 mg daily would not be excluded from the studyXx_NEWLINE_xXIs receiving high dose systemic steroid therapy within 3 days of trial treatment; topical and intra-articular steroid injections are allowed, as are physiologic doses of systemic steroids (=< 10 mg of prednisone equivalent daily)Xx_NEWLINE_xXImmunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of BI 754091Xx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc); any use of corticosteroids EITHER for > 14 days OR at dosages > 20 mg/day of prednisone or equivalent is prohibitedXx_NEWLINE_xXRequirement for concomitant high dose corticosteroids\r\n* EXCEPTION: Patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for adrenal insufficiency, rheumatoid arthritis, etcXx_NEWLINE_xXConfirmed diagnosis of steroid refractory aGvHD defined as patients administered high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:Xx_NEWLINE_xXRequirement for an increase in the corticosteroid dose to methylprednisolone ?2 mg/kg/day (or equivalent prednisone dose ?2.5 mg/kg/day) , ORXx_NEWLINE_xXFailure to taper the methylprednisolone dose to <0.5 mg/kg/day (or equivalent prednisone dose <0.6 mg/kg/day) for a minimum 7 days.Xx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration [> 14 days] of > 10 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXNo steroids are permitted within 28 days of C1D1; or doses < 10 mg/day prednisone equivalent or levels necessary for physiologic replacementXx_NEWLINE_xXStable or decreasing steroid dose (=< 4 mg/day) at time of post-external beam radiation therapy (XRT) adjuvant TMZ initiation; if patients are decreasing steroid use, once they are at 2 mg/day, they may be supplemented with hydrocortisone, at the discretion of the treating oncologistXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration are excludedXx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once dailyXx_NEWLINE_xXPatients who are on high-dose steroids (doses > 10 mg/day of prednisone or equivalent) or immune suppression medications; NOTE: Patients on high-dose steroids (doses > 10 mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least 3 days prior to starting on the study drugsXx_NEWLINE_xXOngoing or recent (within 21 days prior to study entry) use of high dose oral corticosteroids (>= 2 mg of dexamethasone daily or equivalent); intranasal and/or inhaled corticosteroid use is permittedXx_NEWLINE_xXTherapeutic doses of corticosteroids within 14 days prior to study entry, defined as > 20 mg/day of prednisone, or equivalent; topical and/or inhaled steroids are permittedXx_NEWLINE_xXConcomitant disease which requires continuous therapy with corticosteroids at doses equivalent to prednisolone >20 mg/day.Xx_NEWLINE_xXHigh doses of systemic corticosteroids within 7 days prior to first dosing; high dose is considered as > 20 mg of dexamethasone a day (or equivalent) for > 7 consecutive daysXx_NEWLINE_xXPatients must be on a stable or decreasing dose of corticosteroids within 5 days prior to CT scan or MRI (which is done to determine eligibility); patients must be on no more than 8 mg a day but an attempt should be made to keep the dose at 4 mg or less; please contact the PI if doses of > 4 mg are neededXx_NEWLINE_xXMust not have required the use of additional immunosuppressive agents other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of >10 milligrams prednisone or equivalent per day.Xx_NEWLINE_xXAble to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on day -3Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune diseaseXx_NEWLINE_xXClinically significant and ongoing immune suppression including, but not limited to: systemic immunosuppressive agents such as cyclosporine or corticosteroids (at an equivalent dose of 0.5 mg prednisone/kg per day, or higher), chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXParticipant may be receiving steroid therapy at time of enrollment (stable dose of ? 4 mg/day of dexamethasone or steroid equivalent).Xx_NEWLINE_xXPatients who have received a cumulative doxorubicin equivalent of > 375 mg/m^2 total lifetime doseXx_NEWLINE_xXPatients may be on steroids prior to initiation of treatment, provided that, by cycle 1 day 1, steroids use was tapered down to less than or equal to 20 mg of prednisoneXx_NEWLINE_xXOngoing glucocorticoids (prednisone > 10 mg daily, or equivalent); higher doses (> 10 mg daily) are permitted for up to 5 days to help control disease related symptomsXx_NEWLINE_xXChronic use (> 2 weeks) of corticosteroids (prednisone >= 10 mg/24 hour [hr] equivalent) within 4 weeks of screeningXx_NEWLINE_xXPatients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy as defined no greater than 20 mg of prednisone daily) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXPlanned use of corticosteroids (> 10 mg/day prednisone or equivalent) or other systemic immunosuppression within 4 days prior to leukapheresis; topical and/or inhaled steroids are permittedXx_NEWLINE_xXPlanned use of corticosteroids (> 10 mg/day prednisone or equivalent) or other systemic immunosuppression is not permitted within 72 hours prior to JCAR014 infusion; topical and/or inhaled steroids are permitted.Xx_NEWLINE_xXPatients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptableXx_NEWLINE_xXEXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptableXx_NEWLINE_xXEXCLUSION CRITERIA FOR TNBC: Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptableXx_NEWLINE_xXConcurrent systemic steroid therapy higher than physiologic dose (> 7.5 mg/day of prednisone or equivalent)Xx_NEWLINE_xXIs taking > 4mg/day of dexamethasone or its equivalent at the start of immunotherapy or has required > 4mg/day of dexamethasone or its equivalent for 3 consecutive days within 1 week of starting treatmentXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Current use of systemic corticosteroids at doses ? 10 mg prednisone daily or its equivalent; those receiving < 10 mg daily may be enrolled at discretion of investigator; inhaled steroids are allowed\r\n* For pediatric patients, physiologic replacement hydrocortisone at doses 6-12 mg/m^2/day is allowed; equivalently dosed alternative steroids are allowed at discretion of investigator, though not to exceed 10mg prednisone per day; inhaled steroids are allowedXx_NEWLINE_xXPRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Current use of systemic corticosteroids at doses ? 10 mg prednisone daily or its equivalent; those receiving < 10 mg daily may be enrolled at discretion of investigator; inhaled steroids are allowed\r\n* For pediatric patients, physiologic replacement hydrocortisone at doses 6-12mg/m^2/day is allowed; equivalently dosed alternative steroids are allowed at discretion of investigator, though not to exceed 10mg prednisone per day; inhaled steroids are allowedXx_NEWLINE_xXThe use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least 2 weeks; low-dose steroid use (=< 10 mg of prednisone or equivalent) as corticosteroid replacement therapy is allowedXx_NEWLINE_xXPrior therapy resulting in cumulative epirubicin dose >= 900 mg/m^2 or cumulative doxorubicin dose >= 500mg/m^2 or equivalent dose of another anthracyclineXx_NEWLINE_xXIf patient is on steroids, patient must be on a stable or decreasing dose of steroids for 5 days, no more than 2 mg dexamethasone (or equivalent) total per day at the time of screening and consent; if on steroids at the time of screening, the dose will need to be tapered and discontinued at least 5 days prior to CMV T cell infusionXx_NEWLINE_xXPatients must not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for 14 days before apheresis and CAR T-cell infusion; patients must also not take corticosteroids at doses higher than 5 mg/day of prednisone or equivalent at any time after the CAR T cell infusionXx_NEWLINE_xXSteroids within 3 weeks prior to event 1, except:\r\n* =< 10 mg prednisone or equivalent per day\r\n* Steroid with little to no systemic absorption (ie, topical or inhaled steroids)Xx_NEWLINE_xXPatients who have received prior immunotherapy whose side effects have resulted in a requirement of immunosuppressive medications (> 10 mg of prednisone daily or equivalent daily steroid daily, or infliximab, cyclosporine or equivalent immunosuppressive medication) or who have other autoimmune conditions that require immunosuppressive medications as above at the time of screening are excludedXx_NEWLINE_xXSubject requires escalating or chronic supraphysiologic doses of corticosteroids > 2 mg dexamethasone or equivalentXx_NEWLINE_xXNo prior treatment except a prior limited-field radiotherapy, a short course of glucocorticoids =< 25 mg daily of prednisone equivalent which must cease prior to day 1 of cycle 1, and/or cyclophosphamide for an urgent lymphoma related problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of > 10 mg prednisone daily or equivalent at time of first dose of trial treatmentXx_NEWLINE_xXPatients who are on steroids (> 10 mg/day or equivalent) or immune suppression medicationsXx_NEWLINE_xXPatients who are on high dose steroid (equivalent of prednisone more than 10 mg a day) or immune suppression medicationsXx_NEWLINE_xXCorticosteroid use > 4 mg/day at time of consentXx_NEWLINE_xXUnstable, symptomatic brain metastases; Note: participants whose symptoms are controlled on a stable dose of corticosteroids (=< 20 mg prednisone equivalent per day) for at least 2 weeks will be eligibleXx_NEWLINE_xXSteroid therapy for indications other than GVHD at doses > 0.5 mg/kg/d of methylprednisolone or equivalent within 7 days prior to initiation of GVHD treatmentXx_NEWLINE_xXPatients with clear cell histology must have demonstrated: 1) progression on at least one prior anti-angiogenic agent unless intolerable; AND 2) progression on at least one agent that blocks the PD-1 pathway unless felt by the treating physician to be contraindicated (examples include but are not limited to: patients with autoimmune disease or patients requiring systemic steroids greater than 10 mg/day prednisone or its equivalent) or if they have been discontinued due to toxicity; prior rapalogues are allowedXx_NEWLINE_xXOther concurrent immunotherapy (eg, immunosuppressants or chronic use of systemic corticosteroids, with the exception that low-dose corticosteroids [50 mg/day prednisone or equivalent corticosteroid] are allowed; these should be discussed with the Medical Monitor)Xx_NEWLINE_xXMust not have a concurrent medical condition requiring use of systemic corticosteroids with prednisone > 10 mg per dayXx_NEWLINE_xXAt least 2 weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except prednisone or equivalent - up to 10 mg per day is allowed)Xx_NEWLINE_xXPrimary immunodeficiency and need for chronic steroid therapy, exception: patients on chronic physiological dose of steroid equivalent to prednisone < 10 mg/day is allowedXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXPHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXPHASE II STUDY NON-SMALL CELL LUNG CANCER (COHORT 2; MEDI+O AND MEDI+C) AND SMALL CELL LUNG CANCER (COHORT 3; MEDI+O ONLY) ELIGIBILITY CRITERIA:\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal, inhaled, ophthalmological, or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid; in the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of MEDI4736 is 7 daysXx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day of prednisoneXx_NEWLINE_xXHave received systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses) within one week prior to first dose; Note: systemic steroid therapy is allowed for subjects on replacement therapy as long as prednisone =< 10 mg or its steroid equivalent, and those patients should continue at the same dose through the trialXx_NEWLINE_xXSystemic corticosteroids < 1 week prior to Day 1 in Phase 1a. Subjects may receive stable physiologic replacement doses of glucocorticoids (up to the equivalent of 10 mg daily prednisone) as maintenance therapy for adrenal insufficiency.Xx_NEWLINE_xXPatients must be on single immune suppression therapy with either tacrolimus or cyclosporine at the time of CD8+ memory T-cell infusion; prednisone at a physiologic dose of 5 mg per day or less is allowedXx_NEWLINE_xXPatients who are on high dose steroid (> 10 mg daily of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > 10mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least 3 days prior to starting on the study drugsXx_NEWLINE_xXPatients receiving systemic steroids ? 10mg/day of prednisone or the equivalentXx_NEWLINE_xXIf on corticosteroids, a dose of < 1 mg/kg prednisone per day or equivalent that has been stable for ? 21 days prior to the first dose of PRTX-100. High-dose pulse steroid therapy is NOT allowed within 14 days prior to the first dose of PRTX-100.Xx_NEWLINE_xXConcurrent use of corticosteroids equivalent of prednisone at a dose > 0.5 mg/kgXx_NEWLINE_xXPrevious treatment with complete cumulative doses of daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones that is equivalent to a total dose of > 200 mg/m^2 doxorubicinXx_NEWLINE_xXPatients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone) corticosteroid for at least one week prior to study registrationXx_NEWLINE_xXUse of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; dexamethasone, or other corticosteroid medications, if used in the peri-operative period must be tapered to no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration; topical corticosteroids are acceptableXx_NEWLINE_xXFailure to respond to corticosteroids, defined as:\r\n* Progression of chronic GVHD despite optimal first line therapy (> 0.5 mg/kg/day of prednisone dose equivalent [PDE] for two weeks) or\r\n* No improvement after 4-8 weeks of sustained therapy; sustained therapy should include 2 weeks of > 0.5 mg/kg/day of PDE or\r\n* Inability to taper steroid dosage to less than 0.5 mg/kg/day of PDE without worsening of chronic GVHD or \r\n* Need for second or third line therapy beyond corticosteroids and calcineurin inhibitors or sirolimus, irrespective of other criteriaXx_NEWLINE_xXSystemic corticosteroid therapy > 2 mg of dexamethasone or equivalent per day at study entryXx_NEWLINE_xXPatients who require emergent use of systemic steroids, chronic use of prednisone (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or radiotherapy.Xx_NEWLINE_xXPatients with a condition requiring chronic systemic treatment with either corticosteroids(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of treatment start. Inhaled or topical steroids, and adrenal replacement steroid doses> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to equal or less than 0.5 mg/kg/day prednisone (or equivalent).Xx_NEWLINE_xXReceiving corticosteroids > 20 mg of prednisone per day (or equivalent); Note: the dose should be noted on the medication record each cycleXx_NEWLINE_xXChronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).Xx_NEWLINE_xXNo autoimmune disease or chronic steroids (dose of > 10 mg/day prednisone equivalent) or other immunosuppressive medications within 7 days of randomization (for MSI-H nivolumab group)Xx_NEWLINE_xXIf history of exposure to anthracyclines during perioperative treatment, the following cumulative doses of anthracyclines must be less than:\r\n* Epirubicin < 720 mg/m^2\r\n* Doxorubicin or liposomal doxorubicin < 360 mg/m^2\r\n* Mitoxantrone > 120 mg/m^2 and idarubicin > 90 mg/m^2\r\nIf more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m^2 of doxorubicinXx_NEWLINE_xXPatients who are on high dose steroid (e.g. > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)Xx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids equal to or less than 0.5 mg/kg/day of prednisoneXx_NEWLINE_xXClinical status to allow tapering of steroids to less than 0.5 mg/kg/day prednisone or equivalentXx_NEWLINE_xXResearch participant must not require more than 2 mg three times daily (TID) of dexamethasone on the day of PBMC collection.Xx_NEWLINE_xXStudy-Specific Exclusion\r\n* Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study\r\n* History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab\r\n* Dependence on corticosteroids:\r\n** If the participant is undergoing leukapheresis: physiological replacement doses of steroids are allowed - prednisone no more than 7.5 mg, hydrocortisone less than 12 mg.m^2/day\r\n*** However, all participants must be able to reduce steroid requirement to no more than physiological replacement doses prior to start of lymphodepletion\r\n* Active autoimmune disease requiring systemic immunosuppressive therapyXx_NEWLINE_xXUse of full-dose anticoagulant therapy; use of daily aspirin up to 325 mg per day is permittedXx_NEWLINE_xXIf research participant is undergoing leukapheresis, he/she must be at least 2 weeks from having received the last dose of immunosuppressant medications\r\n* Exceptions:\r\n** Steroids and tyrosine kinase inhibitors are allowed up to 7 days prior to leukapheresis\r\n** Research participant cannot be on more than 5 mg prednisone or equivalent doses of other corticosteroids at the time of leukapheresisXx_NEWLINE_xXPatients requiring high doses of glucocorticosteroids (? 0.3 mg/kg prednisone or its equivalent)Xx_NEWLINE_xXReceipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids > 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial.Xx_NEWLINE_xXFull resolution of ipilimumab related adverse events (AEs) to baseline (including immune related adverse events [irAEs]) off of steroid treatment (> 10 mg/day prednisone or equivalent dose) for irAEs for at least two weeks prior to first dose of study drug\r\n* No history of severe irAEs from ipilimumab of Common Terminology Criteria for Adverse Events (CTCAE) grade 4 requiring steroid treatment; no history of CTCAE grade 3 requiring steroid treatment (> 10 mg/day prednisone or equivalent dose) for > 12 weeks\r\n* Minimum of four weeks (wash out period) from the last dose of ipilimumabXx_NEWLINE_xXPatient is on chronic systemic steroid therapy (> 10 mg/kg prednisone or equivalent) within two weeks before the planned date for first dose randomized treatment or on any other form of immunosuppressive medication (premedication with corticosteroid for nausea is permitted)Xx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to equal or less than 0.5 mg/kg/day prednisone (or equivalent)Xx_NEWLINE_xXPatients who are currently receiving chronic (> 14 days) treatment with corticosteroids at a dose >= 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drugXx_NEWLINE_xXThe use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least 2 weeks; low-dose steroid use (=< 10 mg of prednisone or equivalent) as corticosteroid replacement therapy is allowedXx_NEWLINE_xXSteroid use is allowed as long as dose has not increased within 2 weeks of scheduled M032 administration; whenever possible, the patient should be on a steroid dose that is equivalent to a dexamethasone dose of =< 2 mg daily at the time of treatmentXx_NEWLINE_xXRequired steroid increase within 2 weeks of scheduled M032 administration; when possible, the patient should be on a dexamethasone equivalent dose of =< 2 mg daily at the time of treatmentXx_NEWLINE_xXPatients are allowed up to two cycles of high dose steroids (maximum total dose of 320 mg dexamethasone or equivalent) if needed for symptomatic disease before study enrollmentXx_NEWLINE_xXRegular treatment with corticosteroids during the 4 weeks prior to the start of cycle 1, unless administered for indications other than NHL at a dose equivalent to =< 30 mg/day prednisoneXx_NEWLINE_xXMedical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent)Xx_NEWLINE_xXPrimary immunodeficiency and need for chronic steroid therapy, however prednisone is allowed at < 10 mg/day (Turnstile I)Xx_NEWLINE_xXActive GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent)Xx_NEWLINE_xXSystemic corticosteroid therapy must be at a dose of =< 4 mg of dexamethasone or equivalent per day during the week prior to day 1Xx_NEWLINE_xXAble to be off of corticosteroids and any other immune suppressive medications beginning on day -3 and continuing until 30 days after the infusion of the CIML NK cells; however, use of low-level corticosteroids is permitted if deemed medically necessary; low-level corticosteroid use is defined as 10 mg or less of prednisone (or equivalent for other steroids) per dayXx_NEWLINE_xXCurrent or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (> 325 mg/day)Xx_NEWLINE_xXPatients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptableXx_NEWLINE_xXPatients concurrently taking the following drugs are excluded: mycophenolate, cyclosporine, prednisone > 20 mg/day, or immunosuppressive agentsXx_NEWLINE_xXPatients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone) corticosteroid for at least one week prior to study registrationXx_NEWLINE_xXUse of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; patients must be on no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration; topical corticosteroids are acceptableXx_NEWLINE_xXIf receiving corticosteroids, ? 20 mg/day prednisone or equivalent and unchangedXx_NEWLINE_xXThe subject can be on one or more of the following: prednisone (or equivalent corticosteroid) dose =< 20 mg, daily mycophenolate mofetil dose =< 2000 mg/d and cyclosporine/tacrolimus at =< therapeutic blood trough levels; the doses listed are the highest allowed for eligibilityXx_NEWLINE_xXHave not received any leukemia treatment within 1 week prior to starting study drug; corticosteroids up to 20 mg of prednisone (or equivalent) is allowable throughout the study; doses > 20 mg prednisone (or equivalent) are NOT permitted; doses of steroids =< 20 mg of prednisone (or equivalent) are permitted; hydroxyurea is allowed prior to enrollment and after the start of the study drug for the control of peripheral leukemic blasts in subjects with leukocytosis per physician discretionXx_NEWLINE_xXCurrent use of systemic corticosteroids > 0.5 mg/kg/dayXx_NEWLINE_xXPatients with active (grade 2-4) acute graft vs. host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring high doses of glucocorticosteroid (> 0.5 mg/kg/day prednisone or its equivalent) as treatmentXx_NEWLINE_xXPatients on total daily dose of dexamethasone greater than 16 mgXx_NEWLINE_xXPatients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD, or an overt autoimmune disease (e.g. hemolytic anemia) requiring glucocorticosteroid treatment (> 0.5 mg/kg/day prednisone or its equivalent) as treatmentXx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone bidXx_NEWLINE_xXPatients needing more than 8 mg dexamethasone per day at the time of start of WBRT will not be eligible to participate in the study; however, patients will be allowed entry into the study if it is medically safe to reduce the daily dose of dexamethasone to 8 mg or less from the day of the start of WBRT; the dexamethasone dose for such patients may be increased beyond 8 mg per day during the course of treatment if medically necessary; this increased need for dose should be communicated to the study’s principal investigator, Dr Mohindra at the University of MarylandXx_NEWLINE_xXGrade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.Xx_NEWLINE_xXChronic systemic corticosteroid use (ie, prednisone > 10 mg QD or the equivalent of longer duration than 8 weeks for any medical condition) or history of chronic corticosteroid use (longer than 8 weeks duration) within the past 6 months; treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ? 10 mg QD or the equivalent, and patients must have no history of adrenal crisis. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptableXx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of > 20 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXPatients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone) corticosteroid for at least one week prior to study registrationXx_NEWLINE_xXUse of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; dexamethasone, or other corticosteroid medications, if used in the peri-operative period and/or during radiotherapy, must be tapered (no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone) for at least one week before study registration; topical corticosteroids are acceptableXx_NEWLINE_xXReceiving corticosteroids above physiological dosing (> 5 mg per day of prednisone) within 28 days prior to anti-CD19-CAR-transduced T cell administrationXx_NEWLINE_xXMedical need for the continuous administration of any drugs which affect CYP3A4 though the use of low dose glucocorticoids (e.g. dexamethasone =< 4 mg daily or equivalent) for anorexia and /or nausea is permittedXx_NEWLINE_xXCondition requiring active systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medicationsXx_NEWLINE_xXSubject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to first dose of study treatment. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone) are allowed.Xx_NEWLINE_xXPatient with any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 14 days before randomizationXx_NEWLINE_xXPatients must have clinical aGvHD and pathologic findings consistent with the diagnosis by biopsy of at least 1 involved site and treated initially with steroids at prednisone-equivalent doses ?1 mg/kg/day, and i) worsening of GvHD manifestations across any interval of at least 2 days before tapering of steroid doses has begun, or ii) persistence of grade II to IV aGvHD across any interval of at least 7 days without improvement during steroid treatment at any prednisone-equivalent dose >0.4 mg/kg/day or at any lower dose in patients with contraindication to continued treatment at higher steroid doses because of severe steroid-related toxicity (e.g., myopathy), or iii) initial response of GvHD manifestations followed by exacerbation of aGvHD across any interval of at least 3 days while tapering glucocorticoid treatment at any prednisone-equivalent dose >0.4 mg/kg/day or at any lower dose in patients with contraindication to continued treatment at higher steroid doses because of severe steroid-related toxicity (e.g., myopathy).Xx_NEWLINE_xXAbility to be off prednisone and other immunosuppressive drugs (< 1 mg/day) for at least 3 days prior to and while receiving ALT-803Xx_NEWLINE_xXConcurrent need of use of corticosteroids > 10 mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);Xx_NEWLINE_xXUse of any medication or herbal products that may have hormonal anti-prostate cancer activity and/or are known to modulate PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollmentXx_NEWLINE_xX?2 weeks for topical therapy (including steroids, retinoids, nitrogen mustard or imiquimod) Topical steroids (maximum strength: medium potency) and oral steroids (?10 mg prednisone equivalent/day) are allowed, if the patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.Xx_NEWLINE_xXConcomitant corticosteroid use, systemic or topical, for treatment of skin disease. However, topical steroids (maximum strength: medium potency) and oral steroids (?10 mg prednisone equivalent/day) are allowed, if patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.Xx_NEWLINE_xXPatients on systemic corticosteroids (>10 mg prednisone per day or equivalent) or other systemic immunosuppressive drugsXx_NEWLINE_xXNo chronic systemic corticosteroids (defined as the equivalent of prednisone >= 20 mg orally [PO] daily for > 6 months during the past year)Xx_NEWLINE_xXClinical spinal cord compression syndromes (unless patient has undergone treatment, for example, surgery or radiation therapy, and neurological findings are ? Grade 1 and patient is off corticosteroids for spinal cord edema or on a stable regimen of < 10 mg/day prednisone equivalentXx_NEWLINE_xXConcurrent use of systemic steroids with the exception of chronically administered steroids equivalent to ? 10 mg/day prednisone if patient has been on this therapy for ?1monthXx_NEWLINE_xXPatients who are receiving high dose steroids (more than a dexamethasone-equivalent dose of 4 mg per day).Xx_NEWLINE_xXReceiving systemic steroids exceeding 10 mg prednisone or equivalent, or unstable on steroid medication, during the 3 weeks immediately preceding enrollmentXx_NEWLINE_xXAutoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that is uncontrolled or requires >20 mg daily (QD) of prednisone (or equivalent) to maintain hemoglobin >8.0 g/dL or platelets >10,000 ?L without transfusion supportXx_NEWLINE_xXChronic use (>2 weeks) of greater than physiologic doses of corticosteroid agent (dose equivalent to ?10mg of prednisone) within 28 days of 1st day of study drug treatment & during treatmentXx_NEWLINE_xXChronic or long-term corticosteroids: ?0.5 mg/kg/day of oral prednisolone or equivalentXx_NEWLINE_xXSporadic corticosteroids: ?1 mg/kg/day of oral prednisolone or equivalent for 2 or more short courses of > 3 daysXx_NEWLINE_xXSystemic corticosteroids at physiologic doses ?10 mg/day of prednisone or equivalent are permitted;Xx_NEWLINE_xXChronic treatment for more than 6 months with systemic corticosteroids at doses above 10 mg prednisolone or equivalent before study entryXx_NEWLINE_xXImmunosuppressive or systemic hormonal therapy (> 10 mg daily prednisone equivalent) within 2 weeks prior to first administration of IMP and during study; allowed therapies are specified in the protocol.Xx_NEWLINE_xXPrednisone dose ? 20 mg/dayXx_NEWLINE_xXShort course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication within 7 days prior to day 1 of protocol therapy; stable ongoing corticosteroid use (i.e. at least 30 days) up to an equivalent dose of 20 mg of prednisone is permissibleXx_NEWLINE_xXPatients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomizationXx_NEWLINE_xXMedical condition requiring any form of chronic systemic immunosuppressive therapy (steroid or other) except physiologic replacement doses of hydrocortisone or equivalent (no more than 30 mg hydrocortisone or 10 mg prednisone equivalent daily) for < 30 days duration.Xx_NEWLINE_xXDexamethasone at cumulative doses of greater than 160 mg or equivalent <3 weeks prior to study Day 1 is not allowed. Use of topical or inhaled steroids is acceptableXx_NEWLINE_xXPatients receiving systemic steroids ? 10mg/day of prednisone or the equivalentXx_NEWLINE_xXPatients concurrently taking the following drugs are excluded: mycophenolate, cyclosporine, prednisone > 20 mg/day, or immunosuppressive agentsXx_NEWLINE_xXChronic systemic steroid therapy defined as prednisone or equivalent 10 mg/day or greater;Xx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): The patient has to be on first-line TKI therapy (the same TKI) for at least 2 years prior to registration\r\n* Dasatinib: 50 – 180 mg per day\r\n* Imatinib: 200 – 800 mg per day\r\n* Nilotinib: 300 – 400 mg every 12-24 hoursXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): No current use of corticosteroids; EXCEPTION: Low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permittedXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): No current use of corticosteroids; EXCEPTION: Low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permittedXx_NEWLINE_xXPatients requiring corticosteroids use at doses greater than prednisone 10 mg daily equivalent (use of inhaled steroids, and short-term steroid for radiologic contrast allergy, or treatment of immune-related adverse events are allowed)Xx_NEWLINE_xXSystemic (oral/intravenous [IV]/intramuscular [IM]) corticosteroids; patients on chronic stable dose of steroids at an equivalent dose of prednisone ? 10 mg daily may be permitted to enroll at the discretion of principal investigatorXx_NEWLINE_xXParticipants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment except for adrenal replacement steroid doses > 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note: treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating study treatment is permittedXx_NEWLINE_xXChronic use of corticosteroids in excess of prednisone 20 mg/day or its equivalentXx_NEWLINE_xXSystemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.Xx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration [> 14 days] of > 60 mg/day of prednisone or equivalent) within 28 days of the first dose of study drugXx_NEWLINE_xXReceiving immunosuppressive agents or > 10 mg daily prednisone or equivalent of corticosteroidsXx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune diseaseXx_NEWLINE_xXSystemic corticosteroid therapy, > 8 mg of dexamethasone daily (or equivalent) at study enrollmentXx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomizationXx_NEWLINE_xXPrior treatment with small molecule BET family inhibitor or receiving steroids >the equivalent of 10mg prednisone dailyXx_NEWLINE_xXHave received a cumulative dose of corticosteroid ? 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first Investigational Medicinal Product (IMP) administration.Xx_NEWLINE_xXEvidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Receiving systemic immunosuppressive therapy including prednisone > 10 mg per day (or equivalent), tacrolimus, everolimus, sirolimus, mycophenolate mofetil, etanercept, infliximab, etc. \r\n* Recipients of solid organ, bone marrow, or stem cell transplants; auto transplant recipients are allowed\r\n* Notes: Oral steroid doses =< 10 mg/day of prednisone (or equivalent) are not considered immunosuppressive and are permitted; inhaled and intraarticular corticosteroids are permittedXx_NEWLINE_xXChronic corticosteroid use in excess of the equivalent of prednisone 10 mg once dailyXx_NEWLINE_xXConcomitant high dose corticosteroids except patients may be on chronic steroids (maximum dose 10 mg/day prednisone equivalent) if they are being given for disorders other than myeloma, e.g. adrenal insufficiency, rheumatoid arthritis, etcXx_NEWLINE_xXTreatment with corticosteroids (?10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.Xx_NEWLINE_xXDaily requirement for corticosteroids (> 10 mg prednisone daily or equivalent) (except for inhalation corticosteroids) within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXThe subject requires dexamethasone =< 4 mg daily on a stable doseXx_NEWLINE_xXA condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization; corticosteroids with minimal systemic absorption (inhaled or topical steroids) and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXOngoing corticosteroids for indications other than multiple myeloma allowed as long as the dose does not exceed 10 mg of prednisone per day or equivalentXx_NEWLINE_xXDOSE ESCALATION COHORT: Subjects who are receiving an immunosuppressive treatment for any reason, including chronic use of systemic steroid or prednisone equivalent at doses ? 10 mg/day within 14 days prior to the first dose of study treatment; use of inhaled or topical steroids or systemic corticosteroids < 10 mg is permittedXx_NEWLINE_xXDOSE EXPANSION COHORT: Subjects who are receiving an immunosuppressive treatment for any reason, including chronic use of systemic steroid or prednisone equivalent at doses ? 10 mg/day within 14 days prior to the first dose of study treatment; use of inhaled or topical steroids or systemic corticosteroids < 10 mg is permittedXx_NEWLINE_xXPrevious autoimmune complication from PD-1 or PD-L1 requiring discontinuation of therapy or treatment with steroids (ongoing treatment with more than 10 mg of prednisone or steroid equivalent daily, excluding inhaled or topical steroids).Xx_NEWLINE_xXRequires escalating or chronic supraphysiologic doses of corticosteroids (> 10 mg/day prednisone equivalents)Xx_NEWLINE_xXSystemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed; patients may be using topical or inhaled corticosteroidsXx_NEWLINE_xXNeed for daily corticosteroids at high doses (prednisone >= 20 mg daily, or an equivalent) is prohibited from 28 days prior to first dose and during treatment with ibrutinib; brief (up to 7 days) and episodic use of systemic corticosteroids for other general conditions (e.g. pre-medication for radiographic imaging due to intravenous [IV] contrast allergy, chronic obstructive pulmonary disease [COPD] exacerbation, poison ivy, etc.) is allowedXx_NEWLINE_xXAble to be off prednisone or other immunosuppressive medications other than that prescribed per protocol for at least 3 days prior to day 0Xx_NEWLINE_xXChronic use of corticosteroids in excess of prednisone 20 mg/day or its equivalentXx_NEWLINE_xXChronic use (? 2 weeks) of corticosteroids (? 10 mg/24 hour equivalent prednisone) within 4 weeks of Baseline/Cycle 1 Day 1 visit.Xx_NEWLINE_xXChronic corticosteroid use in excess of the equivalent of prednisone 10 mg once dailyXx_NEWLINE_xXConcurrent use of high dose steroids; chronic steroid use of < 2 mg dexamethasone or equivalent per day is permissibleXx_NEWLINE_xXSteroid therapy, or steroid therapy with more than 7 consecutive days of steroids within the prior 4 weeks \r\n* The use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted\r\n* Inhaled or topical corticosteroids are permittedXx_NEWLINE_xXHistory of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of 10 mg or lessXx_NEWLINE_xXAt least 2 weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except for =< 10 mg daily prednisone or equivalent which is permitted during the study)Xx_NEWLINE_xXAny condition requiring > 10 mg/d prednisone equivalentsXx_NEWLINE_xXPatients with a history of severe immune-mediated adverse reactions with ipilimumab: this will be defined as any grade 4 toxicity requiring treatment with corticosteroids (greater than 10 mg/day prednisone or equivalent dose) for greater than 12 weeksXx_NEWLINE_xXHistory of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of 10 mg or less; note: a history of mild asthma not requiring therapy is eligibleXx_NEWLINE_xXSystemic anti-myeloma therapy including systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within 2 weeks prior to the required leukapheresisXx_NEWLINE_xXPatients should not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for any purpose at doses higher than 5 mg/day of prednisone or equivalent dose of another corticosteroid 2 weeks before apheresis and within 2 weeks prior to CAR T-cell infusion, and at any time after the CAR T cell infusionXx_NEWLINE_xXSystemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within 2 weeks prior to either the required leukapheresis or the initiation of the conditioning chemotherapy regimenXx_NEWLINE_xXConcurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the last 4 weeks\r\n* The use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted\r\n* Inhaled corticosteroids are permitted\r\n* The following will not be exclusionary:\r\n** The presence of laboratory evidence of autoimmune disease (e.g. positive antinuclear antibody [ANA] titer) without associated symptoms\r\n** Mild Raynaud’s phenomenon\r\n** History of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of prednisone or equivalent of 10 mg or lessXx_NEWLINE_xXA patient's daily total dose of dexamethasone must be =< 16 mg by day 4Xx_NEWLINE_xXChronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)Xx_NEWLINE_xXActive immunosuppressive therapy, including concurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the prior 4 weeks\r\n* The use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted\r\n* Inhaled corticosteroids are permittedXx_NEWLINE_xXPatients must not be receiving concurrent steroids > 10 mg prednisone (or equivalent)\n             per day.Xx_NEWLINE_xXConcurrent steroids allowed (up to equivalent of prednisone 20 mg daily, on taper or stable dose for at least 2 weeks)Xx_NEWLINE_xXPatients must have clinical evidence* of steroid-refractory acute graft vs host disease (any organ) defined as one of the following:\r\n* Progressive GVHD after at least 3 days on corticosteroids (>= 1 mg/kg of prednisone or equivalent); this means new organ involvement (skin, liver, or intestine) or increased organ specific symptoms sufficient to increase the organ stage by one or more\r\n* No improvement in GVHD after at least 7 days on corticosteroids (>= 1 mg/kg of prednisone or equivalent)\r\n* Patients with protracted acute GvHD who are unable to be tapered below 0.5mg/kg/d of prednisone (without the addition of alternate immunosuppressives) are considered eligibleXx_NEWLINE_xXSystemic corticosteroids within 2 weeks, except low dose regimens (prednisone, ? 20\n             mg/day, or equivalent) which may continue if unchangedXx_NEWLINE_xXCurrent treatment or treatment within 4 weeks of screening with drugs known to reduce\n             serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet,\n             macrolide antibiotics (such as erythromycin, azithromycin), large doses of\n             corticosteroids (>20 mg/day of prednisone or equivalent), or any IV use of\n             corticosteroids. In addition, long-term use (defined as ongoing use for ?4 weeks) of\n             corticosteroids within 8 weeks of screening is prohibitedXx_NEWLINE_xXPatients receiving a stable dose (> 4 weeks) of corticosteroid therapy equivalent to 20 mg of prednisone per day or less are eligibleXx_NEWLINE_xXNo corticosteroids are permitted, except for maintenance therapy for a non-malignant disease or to prevent treatment-related ofatumumab reactions (maintenance therapy dose must not exceed 20 mg/day prednisone or equivalent)Xx_NEWLINE_xXPrior treated brain or meningeal metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administrationXx_NEWLINE_xXImmunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administrationXx_NEWLINE_xXImmunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administrationXx_NEWLINE_xXNo systemic cytotoxic chemotherapy within 4 weeks of enrollment or systemic steroids (except stable doses of prednisone =< 20 mg/day, or up to 4 doses of steroid given for non-therapy reasons) within 4 weeks of enrollmentXx_NEWLINE_xXHas not had prior systemic therapy for multiple myeloma. An emergency course of steroids (defined as no greater than 40 milligram [mg] of dexamethasone, or equivalent per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. In addition, radiation therapy is permitted prior to study entry, during screening, and during Cycles 1-2 of study treatment as needed for lytic bone diseaseXx_NEWLINE_xXPatients must have completed prednisone taper (5 mg - 2.5 mg) prior to randomizationXx_NEWLINE_xXPatients must not have received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to sub-study registration; inhaled or topical steroids, and adrenal replacement doses =< 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPrior systemic glucocorticosteroid use for the treatment of non-malignant disorders is permitted; concurrent use after registration on the study should be restricted to the equivalent of prednisone 10 mg per dayXx_NEWLINE_xXSystemic therapy with corticosteroids at >20 mg/day prednisone or equivalent within 1 week prior to the first dose of study drugXx_NEWLINE_xXOther anti-platelet agents; Aspirin use at doses up to 325 milligrams (mg)/day is permitted.Xx_NEWLINE_xXIf the subject has a history of maximum Grade 1 or 2 GVHD that was treated with systemic steroid (? 0.5 mg/kg/day prednisone equivalents) or other non-steroid systemic IST, the subject must be off all IST for at least 2 weeks, and must have ceased treatment doses of steroids for GVHD (? 0.5 mg/kg/day prednisone equivalents) for at least 4 weeks. o If the subject has a history of Grade 3 or greater GVHD, the subject must be off all systemic IST for 4 weeks o Topical therapy is permitted and does not imply the subject has active acute or chronic GVHD.Xx_NEWLINE_xXSubjects with progressive GVHD (ie, increase in stage in any organ system or any new organ involvement) after 3 days of primary treatment with methylprednisolone ? 2 mg/kg per day (or equivalent).Xx_NEWLINE_xXSubjects with GVHD that has not improved (ie, decrease in stage in at least 1 involved organ system) after 7 days of primary treatment with methylprednisolone ? 2 mg/kg per day (or equivalent).Xx_NEWLINE_xXSubjects who previously began corticosteroid therapy at a lower dose (at least 1 mg/kg per day methylprednisolone) but develop new GVHD in another organ system.Xx_NEWLINE_xXSubjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at 2.0 mg/kg per day, demonstrate response, but progress before a 50% decrease from the initial starting dose of corticosteroids is achieved.Xx_NEWLINE_xXAny corticosteroid therapy for indications other than GVHD at doses of methylprednisolone or equivalent > 1 mg/kg per day within 7 days of enrollment.Xx_NEWLINE_xXRequires treatment with high dose systemic corticosteroids defined as >2 mg/dayXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.Xx_NEWLINE_xXNon-escalating corticosteroid dose (not exceeding more than 16 mg daily of dexamethasone oral) for >= 5 daysXx_NEWLINE_xXImmunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810Xx_NEWLINE_xXPatients receiving corticosteroids for any indication within 7 days before the onset of acute GVHD, except the following: Stable replacement doses of corticosteroids for adrenal insufficiency are permitted (e.g. hydrocortisone total dose of 10-12 mg/m^2/day or prednisone 5-7.5mg daily or equivalent). Corticosteroids administered as premedication before transfusion of blood products or before intravenous medications to prevent infusion reactions are allowed.Xx_NEWLINE_xXSubjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to <= 10 mg prednisone daily).Xx_NEWLINE_xXParticipant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatmentXx_NEWLINE_xXSteroids: Therapeutic systemic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 12 mg/m2/day hydrocortisone or equivalentXx_NEWLINE_xXCurrent need for chronic corticosteroid therapy or other immunosuppressive agents (>= 10 mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids =< 2 weeks prior to starting study drugXx_NEWLINE_xXSteroids: Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 6 - 12 mg/m2/day hydrocortisone or equivalentXx_NEWLINE_xXRegular dose of corticosteroids the 28 days prior to Day 1 of this study or anticipated need for corticosteroids that exceeds prednisone 10 mg/day or equivalent within 28 days prior to the first RO6958688 infusion. Inhaled and topical steroids are permittedXx_NEWLINE_xXSystemic steroid therapy or steroid therapy that cannot be discontinued with more than 7 consecutive days of steroids within the prior 2 weeks\r\n* Note: the use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 15 mg/day) as replacement therapy is permitted; inhaled or topical corticosteroids are permittedXx_NEWLINE_xXPatients needing more than 8 mg dexamethasone per day at the time of start of WBRT will not be eligible to participate in the study; however, patients will be allowed entry into the study if it is medically safe to reduce the daily dose of dexamethasone to 8 mg or less from the day of the start of WBRT; the dexamethasone dose for such patients may be increased beyond 8 mg per day during the course of treatment if medically necessary; this increased need for dose should be communicated to the study’s principal investigator, Dr Mohindra at the University of MarylandXx_NEWLINE_xXRequirement for other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered to be investigational or which would be considered as a treatment of AL amyloidosis. However, participants may be on chronic steroids (maximum dose 20 mg/day prednisone or equivalent) if they are being given for disorders other than amyloidosis (eg, adrenal insufficiency, rheumatoid arthritis, etc.).Xx_NEWLINE_xXDaily requirement for corticosteroids ? prednisone 10 mg/day or equivalent.Xx_NEWLINE_xXNo more than 16 mg dexamethasone (or equivalent) per dayXx_NEWLINE_xXSystemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent;Xx_NEWLINE_xXSteroids: Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 12 mg/m2/day hydrocortisone or equivalentXx_NEWLINE_xXSubjects with Immunotherapy related adverse events requiring high doses of steroids (? 40 mg/day of prednisone) are not eligibleXx_NEWLINE_xXPrior treatment with doxorubicin or other anthracycline at cumulative doses greater than 300 mg/m2 (calculated using doxorubicin equivalent doses: 1 mg doxorubicin = 1 mg Doxil/Caelyx = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)Xx_NEWLINE_xXNeed for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)Xx_NEWLINE_xXSystemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalentXx_NEWLINE_xXSubject received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.Xx_NEWLINE_xXGlucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study dayXx_NEWLINE_xXRegular treatment with corticosteroids within the 2 or 4 weeks prior to the start of Cycle 1, unless administered for indications other than non-Hodgkin's lymphoma at a dose equivalent to < 30 mg/day prednisone/prednisoloneXx_NEWLINE_xXPatients must not be receiving chronic treatment (equivalent of prednisone > 10 mg/day) with systemic steroids or other immuno-suppressive agentXx_NEWLINE_xXChronic use of systemic corticosteroid above an accepted physiologic dose (5mg per day of prednisone or equivalent) within 7 days of enrollment except when used as premedicationXx_NEWLINE_xXSubjects on immunosuppressive medications such as azathioprine, mycophenolate mofetil, cyclosporine or require chronic corticosteroid use (defined as ? 3 months of prednisone dose equivalent of ? 10 mg).Xx_NEWLINE_xXSteroid use equivalent to greater than 20 mg of prednisone within 4 weeks (28 days) prior to Day 1.Xx_NEWLINE_xXChronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids), or any other immunosuppressive drugs.Xx_NEWLINE_xXNo known autoimmune disease requiring active treatment. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ? 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXNo corticosteroids, or on a stable or decreasing dose of ? 10 mg daily prednisone (or equivalent)Xx_NEWLINE_xXNo prior anti-lymphoma therapy. However, for subjects with bulky disease,systemic symptoms, compressive disease, or rapidly progressing adenopathies, pre-phase treatment with 1 mg/kg/day prednisone, or equivalent, for a maximum of 7 days is permitted prior to Cycle 1 Day -6 at the discretion of the Investigator. In exceptional cases, if clinically indicated, a higher dose of steroids and/or a slightly longer duration is allowed for the purpose of urgent symptom management, and the subjects is considered eligible. A washout period does not apply. However the fresh core biopsy mentioned above should be performed before starting prednisone.Xx_NEWLINE_xXPatients requiring daily corticosteroids at a prednisone equivalent of >= 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first doseXx_NEWLINE_xXChronic use (? 2 weeks) of corticosteroids (? 10 mg/24 hr equivalent prednisone) within 4 weeks of Baseline/First Dose.Xx_NEWLINE_xXEXCLUSION FOR TREATMENT: Patients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) following allo-HSCT requiring glucocorticosteroid treatment (> 0.5 mg/kg/day prednisone or its equivalent) as treatmentXx_NEWLINE_xXAt least 4 weeks from last dose of therapeutic glucocorticosteroids. Adrenal replacement doses of glucocorticosteroids (up to the equivalent of 10 mg daily prednisone) are allowed.Xx_NEWLINE_xXConcomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against AITL, within the two weeks prior to treatment start. Concurrent corticosteroids are allowed, provided they are administered at an equivalent prednisone dose of ? 10 mg daily, as premedication for blood products only.Xx_NEWLINE_xXReceived any chemotherapy, immunomodulatory or immunosuppressive therapy, corticosteroids (greater than [>]30 milligram per day [mg/day] prednisone or equivalent) within 28 days prior to randomizationXx_NEWLINE_xXPrior treated brain or meningeal metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administrationXx_NEWLINE_xXImmunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administrationXx_NEWLINE_xXCurrent or recent (within 10 days prior to the first study drug dose) chronic daily treatment with aspirin (> 325 mg/day)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents within 2 weeks prior to cycle 1, day 1; patients who have received acute and/or lowrolment, or anticipation of need for major surgical, a one-time dose of dexamethasone for nausea or chronic use of =< 10 mg/day of prednisone or dose-equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the medical monitor; the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed; prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first receipt of study drugXx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of > 10 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXChronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of randomizationXx_NEWLINE_xXChronic oral or systemic steroid medication use at a dose of > 10 mg/d of prednisone or equivalent (steroids with low systemic absorption [e.g. triamcinolone hexacetonide] injected into joint space are allowed)Xx_NEWLINE_xXRequirement for chronic immunosuppressive medication including systemic corticosteroids above the physiologic dose (30 mg/day hydrocortisone or the equivalent).Xx_NEWLINE_xXAny corticosteroid therapy (for indications other than GVHD) at doses > 1 mg/kg per day methylprednisolone or equivalent within 7 days of randomization.Xx_NEWLINE_xXNo corticosteroid use will be permitted within two weeks prior to study, except for maintenance therapy for a non-malignant disease; maintenance therapy dose may not exceed 20 mg/day prednisone or equivalentXx_NEWLINE_xXSystemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administrationXx_NEWLINE_xXPatients receiving concomitant immunosuppressive agents or chronic corticosteroids (?10 mg of prednisone or equivalent) at the time of first study dose.Xx_NEWLINE_xXSystemic steroids are allowed as long as they are tapered to the equivalent of 20 milligrams (mg) prednisone daily or less by the start of cycle 2Xx_NEWLINE_xXLow dose aspirin (? 100 mg daily).Xx_NEWLINE_xXPatients who are currently receiving chronic (> 14 days) treatment with corticosteroids at a dose equal to or more than 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drugXx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration [> 14 days] of > 10 mg/day of prednisone) within 28 days of the first dose of study drug (prednisone should not be started during screening or be given during the study for treatment of mastocytosis)Xx_NEWLINE_xXRequires escalating or chronic supraphysiologic doses of corticosteroids (> 10 mg/day prednisone equivalents)Xx_NEWLINE_xXThe patient must not be on a corticosteroid dose greater than physiologic replacement dosing defined as 30 mg of cortisone per day or its equivalentXx_NEWLINE_xXPlanned concurrent treatment with systemic high dose corticosteroids; patients may be on a stable low dose of steroids (< 10 mg equivalent of prednisone) for chronic respiratory conditionsXx_NEWLINE_xXParticipants with ongoing corticosteroid use >30 mg per day of prednisone or equivalentXx_NEWLINE_xXHave received a cumulative dose of corticosteroid ? 100 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.Xx_NEWLINE_xXSubjects taking corticosteroids during the last week prior to study treatment, unless administered at a dose equivalent to < 20 mg/day prednisone or prednisolone.Xx_NEWLINE_xXPatients must not require more than 20 mg prednisone or equivalent corticosteroid dailyXx_NEWLINE_xXUse of prednisone (or equivalent corticosteroid dose) for SM up to 10 mg/day or its equivalent is allowed, but it cannot have been started during screening; patients who are on prednisone up to 10 mg/day for medical problems unrelated to SM are also permitted on studyXx_NEWLINE_xXConcurrent steroid use of more than an equivalent of 20 mg/day prednisone (or equivalent)Xx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day prednisone at time of treatmentXx_NEWLINE_xXNo prior therapy for MCL, except: < 2 weeks of steroid therapy for symptom control or local radiation therapy for symptom control if there is measurable disease outside the radiation portal; patients may be on chronic steroids for non-malignant disease if on a stable dose equivalent to =< 20 mg prednisone per dayXx_NEWLINE_xXPatients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids or treatment with low, stable dose of steroid (<10 mg/day prednisone or equivalent) for stable CNS metastatic disease.Xx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeksXx_NEWLINE_xXPatients requiring concurrent systemic steroid therapy higher than physiologic dose (7.5 mg/day of prednisone).Xx_NEWLINE_xXHave received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent, or growth factor treatment within 4 weeks prior to study entryXx_NEWLINE_xXChronic systemic corticosteroid use (ie, prednisone > 10 mg QD or the equivalent); treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ? 10 mg QD or the equivalent, and patients must have no history of adrenal crisis. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptableXx_NEWLINE_xXTreatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administrationXx_NEWLINE_xXSubjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (=< the equivalent of prednisone 10 mg/day) or other immunosuppressives such as azathioprine or cyclosporin A are; for these subjects these excluded treatments must be discontinued at least 2 weeks prior to enrollment for recent short course use (=< 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (> 14 days); in addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on studyXx_NEWLINE_xXSteroids (at prednisone equivalent doses > 10 mg) are not permitted 3 days prior to T cell infusion and concurrently during therapy. Exceptions include use of systemic prednisone equivalent doses =< 10 mg/ day, topical steroids or physiologic replacement dose of steroids for adrenocortical deficiency.Xx_NEWLINE_xXMedical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent); brief (< 15 days) treatment with glucocorticoids (prednisone 100 mg by mouth daily, or equivalent) is acceptableXx_NEWLINE_xXPatients who have evidence of active, noninfectious pneumonitis or have a history of severe pneumonitis that required treatment with steroids are not eligible for this study; (Note: replacement physiologic dose of steroids [prednisone 10 mg daily or equivalent] are allowed)Xx_NEWLINE_xXCurrent or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day)Xx_NEWLINE_xXTreatment with oral or parenteral corticosteroids dosed greater than 40 mg hydrocortisone daily or its equivalent (e.g., prednisone 10 mg, prednisolone 8 mg, or decadron 3 mg) =< 2 weeks of treatment initiation; or a clinical requirement for ongoing systemic immunosuppressive therapyXx_NEWLINE_xXConcurrent treatment with anti -Tumor necrosis factor (TNF) alpha therapies, systemic corticosteroids (prednisone dose >10 mg per day or equivalent) or other immune suppressive drugs within the 2 weeks prior to Screening. Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permittedXx_NEWLINE_xXPatients who are on high dose steroid (i.e. prednisone or equivalent more than 10 mg a day) or immune suppression medicationsXx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of > 10 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXPatient has a medical condition that requires chronic systemic steroid therapy or requires any other form of immunosuppressive medication; however, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study; up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg of prednisone) in the eveningXx_NEWLINE_xXPatients who are on high-dose steroids (doses > 10 mg/day of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > 10mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least 3 days prior to starting on the study drugsXx_NEWLINE_xXDexamethasone dose less than or equal to 4 mg daily at time of study enrollmentXx_NEWLINE_xXImmunosuppressants: patients must be receiving a stable or decreasing dose of dexamethasone for at least 1 week prior to start of therapy AND dexamethasone dose must be =< 0.1 mg/kg/day AND =< a total daily dose of 4 mg/dayXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXUse of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >= 4 mg/day or prednisone >= 20 mg/day), within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; hydroxyurea is permitted up to 24 hours before the first dose of study drug in patients with rapidly-proliferating diseaseXx_NEWLINE_xXPatients must be on a stable or decreasing dose of corticosteroids for 5 days prior to enrollment; patient may be taking therapeutic doses of steroids during the initial dose escalations and prior to defining an RP2D; this should be recorded in the database; once the RP2D has been established, enrollment may be limited based on steroid use;*physiologic replacement doses will be defined on this protocol as no more than 0.75 mg/m^2/day of dexamethasone or equivalent of steroids; doses higher than this will be considered therapeuticXx_NEWLINE_xXHistory of exposure at any time to the following cumulative doses of anthracyclines:\r\n* Doxorubicin or liposomal doxorubicin > 500 mg/m^2\r\n* Epirubicin > 900 mg/m^2\r\n* Mitoxantrone >120 mg/m^2\r\n* Another anthracycline, or more than one anthracycline used in a cumulative dose exceeding the equivalent of doxorubicin 500 mg/m^2Xx_NEWLINE_xXGlucocorticoid therapy within the 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or 1000 mg prednisoneXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic steroid therapy of prednisone ? 10 mg daily or any equivalent dose of corticosteroids.Xx_NEWLINE_xXOther ongoing or prior anti-myeloma therapy; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. q.d. or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment)Xx_NEWLINE_xXShort course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (=< 7 days) must have been discontinued at least 6 days prior to study treatment; stable ongoing corticosteroid use (>= 30 days) up to an equivalent dose of 15 mg of prednisone is permissible\r\n* Topical steroids that have been used for > 3 weeks may be continued (CTCL only)Xx_NEWLINE_xXParticipants must have steroid-refractory cGVHD; steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms; patients with either extensive chronic GVHD or limited chronic GVHD requiring systemic therapy are eligibleXx_NEWLINE_xXOngoing prednisone requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXStable dose of steroids for 5 days, no more than 2 mg dexamethasone (or equivalent) total per dayXx_NEWLINE_xXRequires treatment with high dose systemic corticosteroids defined as dexamethasone > 4 mg/day or bioequivalent for at least 3 consecutive days within 2 weeks of start of study drugXx_NEWLINE_xXParticipants must have steroid-refractory chronic GVHD (cGVHD); steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate glucocorticoids) without complete resolution of signs and symptoms; participants with either extensive or limited chronic GVHD requiring systemic therapy are eligibleXx_NEWLINE_xXParticipants with ongoing prednisone (equivalent) dose requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXPatient requires more than 8 mg of dexamethasone daily or the equivalentXx_NEWLINE_xXAny condition requiring systemic treatment with corticosteroids (>10 mg daily Prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses >10 mg daily Prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSystemic anticoagulation or daily aspirin dose exceeding 325 mg per dayXx_NEWLINE_xXParticipant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatmentXx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutic; patients are allowed to receive corticosteroids for the treatment of non-malignant disorders in doses not to exceed the equivalent of prednisone 20 mg/dayXx_NEWLINE_xXCorticosteroid therapies of > 20 mg/day prednisone, > 4 mg/day dexamethasone, > 80 mg/day hydrocortisone, or equivalent; oral, inhaled, or topical steroids are allowed during study as long as it does not exceed 80 mg/day hydrocortisoneXx_NEWLINE_xXSubjects requiring daily corticosteroids at a prednisone equivalent of > 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day or prednisone equivalent), the discontinuation or dose reduction should be done at least 7 days prior to the first doseXx_NEWLINE_xXParticipants using concomitant corticosteroids are allowed as long as the subject is on the equivalent of 20 mg/day or less of prednisone and has been on a stable dose for at least two weeks prior to initiating therapyXx_NEWLINE_xXCurrent chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone or equivalent [excluding inhaled steroids])Xx_NEWLINE_xXUse of a systemic steroid (> 5 mg prednisone daily or equivalent) =< 4 weeks prior to registrationXx_NEWLINE_xXPhysiologic doses of corticosteroids are allowed (i.e. no more than 10 mg prednisone daily)Xx_NEWLINE_xXUse of herbal products that may decrease PSA levels (i.e., saw palmetto) or systemic corticosteroid greater than the equivalent of 10 mg of prednisone per day during the 4 weeks prior to screening or plans to initiate treatment with the above during the entire duration of the studyXx_NEWLINE_xXUse of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of replacement steroids or > equivalent of 10 mg of prednisone per day within 4 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXPatients who are on chronic steroids for unrelated conditions (i.e. rheumatologic conditions) are not eligible if their total daily dose of steroids is >= 10 mg prednisoneXx_NEWLINE_xXNo current use of corticosteroids; EXCEPTION: low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permittedXx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone bid.Xx_NEWLINE_xXPHASE I: Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once dailyXx_NEWLINE_xXPHASE II: Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once dailyXx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone bidXx_NEWLINE_xXPatients who have previously had > 368 mg/m^2 cumulative dose of daunorubicin or > 368 mg/m^2 daunorubicin-equivalent anthracycline therapy (for example, from prior treatment of solid tumors)Xx_NEWLINE_xXUncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that is uncontrolled or requiring > 20 mg once daily (QD) of prednisone (or equivalent) to maintain hemoglobin > 8.0 g/dL or platelets > 10,000 ?L without transfusion supportXx_NEWLINE_xXOngoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic steroids > 20 mg prednisone (or equivalent) QDXx_NEWLINE_xXCurrent chronic daily treatment (continuous for > 3 months) with corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroidsXx_NEWLINE_xXDexamethasone at cumulative doses greater than 160 mg or equivalent within 14 days prior to the first dose of study treatment is not allowed. Use of topical or inhaled steroids is acceptable.Xx_NEWLINE_xXPatient had prior exposure to a cumulative dose of doxorubicin that exceeded 360 mg/m2 or its equivalent.Xx_NEWLINE_xXOther ongoing anti-myeloma therapy; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. q.d. or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment)Xx_NEWLINE_xXChronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).Xx_NEWLINE_xXPatients with medical conditions that require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication. However, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study: up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening.Xx_NEWLINE_xXUse of systemic corticosteroids equivalent to prednisone 10 mg/day or higher at the time of study entry (inhaled corticosteroids are permitted)Xx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization; inhaled or topical steroids and adrenal replacement steroid doses =< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSteroid refractory cGVHD, defined as having persistent signs and symptoms of cGVHD despite ? 4 weeks of prednisone (or equivalent) dosed at ? 0.25 mg/kg/day (or ? 0.5 mg/kg every other day) within the 12 months prior to screening.Xx_NEWLINE_xXStable dose of ? 1 mg/kg/day of systemic prednisone or equivalent for at least 2 weeks prior to first dose of AMG 592.Xx_NEWLINE_xXReceived prior therapy resulting in a cumulative epirubicin dose > 900 mg/m^2 or cumulative doxorubicin dose > 450 mg/m^2; if another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 450 mg/m^2 doxorubicinXx_NEWLINE_xXTherapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresisXx_NEWLINE_xXShort-course corticosteroids are permissible in the following circumstances:\r\n* Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (< 10 days) must have been discontinued prior to study treatment\r\n* Ongoing administration of a stable dose of corticosteroid therapy (equivalent to < 30 mg prednisone daily and previously received for >= 30 days) is permissible provided there is evidence of measurable disease and there will be no increase in steroid dose during the clinical trialXx_NEWLINE_xXPatients who have a condition that requires systemic treatment with either corticosteroids within 7 days of enrollment (systemic corticosteroid therapy is defined as > 10 mg daily prednisone or its equivalent); or who require other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients requiring daily corticosteroids at a prednisone equivalent of >= 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first doseXx_NEWLINE_xXNo chronic use of systemic steroids greater than the equivalent of 10 mg of prednisone/prednisolone per day within 4 weeks prior to enrollmentXx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone bidXx_NEWLINE_xXPatients on total daily dose of dexamethasone greater than 16 mg/dayXx_NEWLINE_xXUse of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 2 weeks of enrollmentXx_NEWLINE_xXPatients requiring daily corticosteroids at a prednisone equivalent of > 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first doseXx_NEWLINE_xXCurrent need for chronic corticosteroid therapy (>= 10 mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids =< 2 weeks prior to starting study drugXx_NEWLINE_xXPrevious treatment with complete cumulative doses of daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones that is equivalent to a total dose of 240 mg/m^2 doxorubicinXx_NEWLINE_xXRequirement for steroid use greater than 10 mg of prednisone dailyXx_NEWLINE_xXUse of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher at randomizationXx_NEWLINE_xXConcurrent use of aspirin > 100 mg dailyXx_NEWLINE_xXChronic systemic corticosteroid use at supraphysiologic doses (>= 10 mg prednisone per day or equivalent)Xx_NEWLINE_xXShort course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (< 7 days) must have been discontinued at least 7 days prior to study treatment; stable ongoing corticosteroid use (>= 30 days) up to an equivalent dose of 15 mg of prednisone is permissibleXx_NEWLINE_xXAny chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide), immunosuppressive therapy, corticosteroids > 10 mg/day prednisone or equivalent, growth factor treatment (e.g., erythropoietin) or Janus kinase (JAK) inhibitor therapy =< 14 days prior to registrationXx_NEWLINE_xXUp to one cycle of prior therapy is allowed (maximum of 160 mg total dexamethasone [dex] [or equivalent amount of prednisone]), 4 days of melphalan, 4 doses of cyclophosphamide and/or 4 doses of Velcade; at least 4 weeks (wks) has to have had passed since last dose of melphalan, 2 weeks since last Velcade or glucocorticoid doseXx_NEWLINE_xXPatients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).Xx_NEWLINE_xXHas cGvHD that did not respond to high-dose corticosteroids (average 0.5 mg/kg/d prednisone for >= 8 weeks) or second-line systemic therapyXx_NEWLINE_xXCurrent treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).Xx_NEWLINE_xXHCT recipients newly requiring systemic glucocorticoid therapy (at >= 1 mg/kg/day prednisone or equivalent) for chronic GVHD\r\n* In the phase I component of the trial, only those with overall moderate or severe global composite score are eligible\r\n* In the phase II component of the trial, patients of any global composite score are eligible, provided they have need for systemic therapy for chronic GVHDXx_NEWLINE_xXPatients can be enrolled and begin study therapy with ofatumumab within 14 days from initiation of 1 mg/kg/day prednisone for therapy of chronic GVHDXx_NEWLINE_xXPrevious systemic glucocorticoid therapy (at >= 1 mg/kg/day prednisone or equivalent) for chronic GVHD\r\n* Prior systemic glucocorticoid therapy for acute GVHD is permitted\r\n* Prior or ongoing systemic immune suppressive agents (including, but not limited to common examples such as calcineurin inhibitors, sirolimus, mycophenolate mofetil) provided for either prevention or treatment of acute GVHD are permitted and part of routine standard of care\r\n* Patients with progressive, uncontrolled manifestations of acute or chronic GVHD despite >= 1mg/kg/day prednisone (or equivalent) therapy have steroid-refractory disease, and are therefore not eligible for this studyXx_NEWLINE_xXPatients with chronic graft versus host disease (GVHD) that involves 3 or more organs or with a score of 2 or greater in any single organ based on National Institutes of Health (NIH) cGVHD grading and have the following relationship with steroid:\r\n* Dependent disease - cGVHD manifestations requiring a glucocorticoid dose >= prednisone 0.25 mg/kg/day (0.5 mg/kg by mouth every other day) for at least 12 weeks\r\n* Refractory disease - Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednisone 0.5 mg/kg/day (1 mg/kg by mouth every other day) for at least 4 weeks\r\n* Steroid intolerantXx_NEWLINE_xXSystemic steroids that have not been stabilized to the equivalent of =< 10 mg/day of prednisone 7 days prior to the initiation of the trialXx_NEWLINE_xXOral corticosteroids >= 7.5 mg/day prednisone (or prednisone equivalents)Xx_NEWLINE_xXCurrent or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day), or prasugrel (> 10 mg/day)Xx_NEWLINE_xXNo medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent)Xx_NEWLINE_xXMaximum prior cumulative doxorubicin dose of =< 360 mg/m^2 or equivalentXx_NEWLINE_xXPatients receiving any herbal product known to decrease PSA levels (i.e. saw palmetto and prostate cancer [PC]-SPES), or any immunosuppressive dose of systemic or absorbable topical corticosteroid (except prednisone up to 10 mg orally per [q] day, or its equivalent), must discontinue the agent for at least 2 weeks prior to screening; progressive disease must be documented after discontinuation of these productsXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL)-2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents (over the counter [OTC]/herbal/prescribed); immunostimulant agents, other than the study agent; other investigational therapies; or chronic use of systemic corticosteroids (greater than prednisone 10 mg orally per day, or its equivalent)Xx_NEWLINE_xXPrior or concurrent exposure to approved or investigational multiple myeloma treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates, denosumab), or steroids (not exceeding 10 mg prednisone per day or equivalent) are only allowed if given in a stable dose and for a nonmalignant condition; concurrent treatment with erythropoietin-stimulating agents (ESAs) are not allowed.)Xx_NEWLINE_xXPatient on corticosteroids within two weeks prior to study entry, except for prednisone < = 10 mg/day or equivalent for purposes other than treating MCL.Xx_NEWLINE_xXChronic systemic steroids (>10 mg/day Prednisone equivalents) or any other immunosuppressive agentsXx_NEWLINE_xXReceiving chronic therapy for more than 10 days at doses of prednisone greater than 10 mg/day (or equivalent) at the moment of the inclusion. Inhaled and topical corticosteroids are allowed.Xx_NEWLINE_xXNo MF-directed treatment for at least 2 weeks prior to initiation of NS-018, including any use of corticosteroids for Myelofibrosis symptom or blood count management. Low dose corticosteroids ? 10 mg/day prednisone or equivalent is allowed for non-myelofibrosis purposes.Xx_NEWLINE_xXConcomitant high dose corticosteroids other than what is part of treatment protocol (concurrent use of corticosteroids); EXCEPTION: patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for disorders other than myeloma, i.e., adrenal insufficiency, rheumatoid arthritis, etcXx_NEWLINE_xXClinically stable and off or on low dose (no more than 0.1 mg/kg/day, maximum of 4 mg/day dexamethasone) corticosteroid for at least 1 week prior to study enrollmentXx_NEWLINE_xXSystemic corticosteroids (e.g. prednisone >= 12.5 mg/day or dexamethasone >= 2 mg/day) for the purpose of palliating tumor-related symptoms will not be allowed within 1 week of starting treatment on trialXx_NEWLINE_xXCorticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXPatients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy or chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), within 6 months of the first vaccination; treatment or salvage radiation therapy must have been completed at least 4 weeks prior to the first vaccinationXx_NEWLINE_xXSteroid dose not greater than 2 mg/kg prednisone equivalent at time of study enrollment; if patient has steroid refractory GVHD (defined as worsening of GVHD after 3 days of 2 mg/kg prednisone equivalent or no improvement after 7 days of 2 mg/kg prednisone equivalent), time interval from start of steroids to initiation of ECP should not be > 14 daysXx_NEWLINE_xXPrior treatment with cumulative dose of doxorubicin or equivalent exceeding 450 mg/m2Xx_NEWLINE_xXReceiving corticosteroids > 20 mg of prednisone per day (or equivalent)Xx_NEWLINE_xXTreatment including chemotherapy, chemoimmunotherapy, monoclonal antibody therapy, radiotherapy, high-dose corticosteroid therapy (prednisone >= 60 mg daily, or equivalent), or immunotherapy within 3 weeks prior to enrollment or concurrent with this trialXx_NEWLINE_xXNo current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.Xx_NEWLINE_xXIs taking chronic systemic steroids (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXPatients requiring concurrent systemic steroid therapy higher than physiologic dosage (>10mg/day of prednisone or equivalent).Xx_NEWLINE_xXPatients with known central nervous system, meningeal, or epidural disease. Patients with stable brain metastases following definitive local treatment are eligible if steroid requirement is <10 mg/day of prednisone (or equivalent).Xx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of > 20 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXParticipants with a diagnosis of immunodeficiency or who are receiving chronic systemic steroid therapy (doses exceeding 10 mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Physiologic doses of corticosteroids (up to 10 mg/day of prednisone or equivalent) may be used during the studyXx_NEWLINE_xXInability to begin prednisone therapy at a dose of greater than 0.5 mg/kg/day.Xx_NEWLINE_xXAlready receiving sirolimus (for prophylaxis or treatment of acute GVHD) with prednisone at ? 0.25 mg/kg/day (or equivalent) ± additional agents.Xx_NEWLINE_xXHigh dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomizationXx_NEWLINE_xXShort term (<30 days) concurrent systemic steroids ?0.25 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded while receiving vaccine. Patients requiring steroids following previous CNS radiation for metastatic disease are excluded.Xx_NEWLINE_xXOngoing corticosteroid use >30 milligrams per day (mg/day) prednisone or equivalentXx_NEWLINE_xXPatients must have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month; OR at least one pulse of methylprednisolone at a dose at least 1000 mg/d for 3 days on at least one occasion within the previous 6 months prior to the transplant decisionXx_NEWLINE_xXPrior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m2, or of epirubicin dose of greater than 800 mg/m2, or the equivalent dose for other anthracyclines or derivatives (part 2 only).Xx_NEWLINE_xXPatients with active (grade 2-4) acute graft versus (vs.) host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring high doses of glucocorticosteroid (> 0.5 mg/kg/day prednisone or its equivalent) as treatmentXx_NEWLINE_xXPatients must be tapered off systemic steroids to a dosage of less than or equal to 0.25 mg/kg/dayXx_NEWLINE_xXCorticosteroid administration >20 mg/day of prednisone or equivalent within 14 daysXx_NEWLINE_xXInclusion Criteria:\n\n        Male or female subjects may be entered in the study only if they meet all of the following\n        criteria:\n\n          1. Age ?18 and ?65 years of age.\n\n          2. Recipient of an allogeneic hematopoietic stem cell transplantation.\n\n          3. Steroid-resistant acute GvHD, Grade II-IV, defined as: progressive disease after 3\n             days of primary treatment with methylprednisolone 2 mg/kg, or equivalent; or lack of\n             at least a partial response after 7 days of primary treatment with methylprednisolone\n             2 mg/kg or equivalent; or lack of a complete response after 14 days of primary\n             treatment with methylprednisolone 2 mg/kg or equivalent. Note: Subjects who may have\n             received an increase in their steroid dose treatment prior to randomization will be\n             eligible for enrolment.\n\n          4. Evidence of myeloid engraftment (absolute neutrophil count ?0.5 x 10E9/L).\n\n          5. Karnofsky Performance Status score ?50%.\n\n          6. Adequate renal function as defined by serum creatinine ?2 × ULN or calculated CrCl of\n             ?30 mL/min using the Cockroft-Gault equation: Calculated CrCl= ([140-age in years] x\n             [ideal body mass {IBXx_NEWLINE_xXHas primary steroid-refractory GvHD. Steroid-refractory disease is defined as worsening or no improvement in 5 to 7 days of treatment with methylprednisolone 2 milligram per kilogram (mg/kg) or equivalent or lack of a CR after 14 days of primary treatment with methylprednisolone 2 mg/kg or equivalent. Note that participants who develop intestinal GvHD while receiving systemic therapy for other GvHD are still eligible after 5 to 7 days, even if the intestinal GvHD has not been present for the entire duration. Participants who may have received an increase in their steroid dose treatment (example, increased methylprednisolone from 1 mg/kg to 2 mg/kg) before enrollment will be eligible, provided the participant has met the definition of steroid refractory above. Participants who develop toxicity on corticosteroids or who are otherwise medically unable to be dosed to this level, will also be eligible.Xx_NEWLINE_xXAny condition requiring chronic use of moderate/high dose steroids (equivalent to 10 mg QD prednisone).Xx_NEWLINE_xXConcurrent and chronic therapy with corticosteroids (greater than 10mg per day of prednisone or an equipotent dose of another corticosteroid) or any other immunosuppressive drugsXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first study treatment with nivolumab; inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXRequirement for drugs, juices and/or herbs strongly inhibit CYP3A4 from within 7 days prior to D1 of alisertib and throughout treatment; NOTE: glucocorticoids are considered inducers of CYP3A4; however, their use is allowed if patient has been taking a continuous dose of no more than 15 mg/day of prednisone (or its equivalent) for at least 1 month prior to D1 of alisertib; in addition, low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permittedXx_NEWLINE_xXFor Post-allo Part B: Concurrent use of corticosteroids equivalent of prednisone at a dose of greater than 0.5 mg/kgXx_NEWLINE_xXHigh doses of systemic corticosteroids within 7 days prior to first dosing. High dose is considered as > 20 mg of dexamethasone a day (or equivalent) for > 7 consecutive days Exclusion Criteria (Part B):Xx_NEWLINE_xXPrior anthracycline therapy with a cumulative dose of doxorubicin (or equivalent) >= 400 mg/m^2Xx_NEWLINE_xXChronic use of systemic corticosteroids (i.e., >= 10 mg/day prednisone or equivalent)Xx_NEWLINE_xXDiscontinuation of any glucocorticoids prescribed to specifically treat prostate cancer (e.g., as a secondary hormonal manipulation) > 4 weeks prior to receiving first dose of study drug. Glucocorticoids prescribed for a chronic non-cancer-related illness (e.g., asthma or COPD) that is well controlled with medical management are permissible to an equivalent of ? 10 mg prednisone daily.Xx_NEWLINE_xXCurrent use of systemic corticosteroids (> 5 mg prednisone)Xx_NEWLINE_xXReceipt of corticosteroids > 20 mg/day within 4 weeks prior to1st doseXx_NEWLINE_xXSystemic treatment with high dose corticosteroids (greater than Prednisone 10mg daily or equivalent).Xx_NEWLINE_xXMinimal immunosuppression (defined as monotherapy with =< 10 mg prednisone daily, =< 200 mg cyclosporine daily, or =< 2 mg tacrolimus daily) at least 2 weeks prior to scheduled treatmentXx_NEWLINE_xXReceipt of systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.Xx_NEWLINE_xXPatients must be off corticosteroids for at least 2 weeks prior to registration; this includes oral, intravenous (IV), subcutaneous, or inhaled route of administration; patients on chronic corticosteroid for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)Xx_NEWLINE_xXAble to be off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0 (excluding pre-medications); low dose prednisone (< 10 mg/day) is allowed if for indication other than graft-versus-host disease (GVHD)Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Body surface area (BSA) \r\n* Patients must have a BSA >= 0.80 m^2 for dose 5 mg/m^2\r\n* Patients must have a BSA >= 0.65 m^2 for doses of 10 mg/m^2 - 22 mg/m^2 \r\n* Patients must have a BSA >= 0.50 m^2 for doses of 28 mg/m^2 - 36 mg/m^2Xx_NEWLINE_xXImmunosuppressive doses of systemic medication, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 14 days prior to nivolumab administrationXx_NEWLINE_xXThe following medications are prohibited during the study:\r\n* Immunosuppressive agents (except to treat a drug-related adverse event) are prohibited during the study\r\n* Systemic corticosteroids > 10 mg daily prednisone equivalent\r\n* Any concurrent chemotherapy, hormonal therapy, immunotherapy, or investigational agents for treatment of cancer are prohibited during the studyXx_NEWLINE_xXHas, within 2 weeks prior to Day 1, received systemic corticosteroids exceeding prednisone 10 mg per day or equivalent; for other immunosuppressive agents, the exclusionary dose and duration will be determined in consultation with the Medical Monitor.Xx_NEWLINE_xXNeed for current chronic corticosteroid therapy (>= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)Xx_NEWLINE_xXUse of systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day.Xx_NEWLINE_xXConcurrent use of other anti-cancer agents or treatments. NOTE: Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to 20 mg of Prednisone per day as long as the dose has not been adjusted upwards in past 2 weeks prior to study registration.Xx_NEWLINE_xXReceiving a new course of systemic corticosteroids (? 0.5 mg/kg/day) as first-line cGVHD therapy at least 1 day and no more than 21 days prior to first dose of ENTO/Placebo ANDXx_NEWLINE_xXInability to begin systemic corticosteroids therapy at a dose of ? 0.5 mg/kg/day (or equivalent)Xx_NEWLINE_xXActive treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisoneXx_NEWLINE_xXCurrent use of corticosteroids; EXCEPTION: low doses of steroids (=< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of nonhematologic medical conditions; NOTE: previous use of corticosteroids is allowedXx_NEWLINE_xXif receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than 1 mg of dexamethasone a day or equivalent, i.e. 6 mg prednisone or 25 mg hydrocortisone for at least 5 days prior to date of enrollment.Xx_NEWLINE_xXIf receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than 8 mg dexamethasone (or equivalent) for at least 5 days prior to date of enrollment.Xx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to equal or less than 0.5 mg/kg/day prednisone (or equivalent).Xx_NEWLINE_xXCorticosteroid doses greater than equivalent of prednisone 7.5 mg orally (PO) dailyXx_NEWLINE_xXReceiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily.Xx_NEWLINE_xXActive treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisoneXx_NEWLINE_xXPatient requiring systemic, pharmacologic doses of corticosteroids (equivalent to > 60 mg hydrocortisone/day or 2 mg dexamethasone/day). Replacement doses (equivalent to ? 5 mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as needed.Xx_NEWLINE_xXPatient requires systemic, pharmacologic doses of corticosteroids (equivalent to > 60 mg hydrocortisone/day or 2 mg dexamethasone/day). Replacement doses (equivalent to ? 5 mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as needed.Xx_NEWLINE_xXPrior treated CNS metastases must be without MRI evidence of recurrence for at least 4 weeks after treatment. Patients must be off immunosuppressive doses of systemic steroids (? 10 mg/day prednisone or equivalent) for at least 14 days prior to study drug administration, and must have returned to neurologic baseline status postoperatively. • The 4-week period of stability is measured after the completion of the neurologic interventions (ie, surgery and/or radiation).Xx_NEWLINE_xXIn addition to neurosurgery to treat CNS metastases, adjuvant radiation after the resection of CNS metastasis is allowed. Immunosuppressive doses of systemic steroids (doses ? 10 mg/day prednisone or equivalent) must be discontinued at least 14 days before study drug administration.Xx_NEWLINE_xXAny condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug; inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXHave received a cumulative dose of corticosteroid ? 150 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.Xx_NEWLINE_xXIndividuals on a stable ruxolitinib dose of 5 mg once dailyXx_NEWLINE_xXReceiving chronic systemic corticosteroid therapy > 20 mg of prednisone dailyXx_NEWLINE_xXPatients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent)Xx_NEWLINE_xXOngoing corticosteroid use >30 milligrams per day (mg/day) of prednisone or equivalent. Participants receiving corticosteroid treatment with less than equal to (</=) 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1 Day 1)Xx_NEWLINE_xXOngoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ? 10 mg or an equivalent steroid dose), inhaled and topical steroids are permittedXx_NEWLINE_xXOn immunosuppressive or other anti-leukemic therapy, excluding patients receiving glucocorticoids for management of circulating blast count or patients on a stable dose (<20mg/m2/day prednisone or equivalent) of systemic or topical glucocorticoid therapy with ? Grade 1 GvHD or tapering dose of calcineurin inhibitorXx_NEWLINE_xXActive autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of less than or equal to (</=) 10 mg/day prednisoneXx_NEWLINE_xXChronic daily treatment with corticosteroids (dose > 10 mg/day methylprednisolone equivalent) excluding inhaled steroidsXx_NEWLINE_xXRequirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of SL-701 treatment.Xx_NEWLINE_xXActive treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisoneXx_NEWLINE_xXReceiving chronic immunosuppressive therapies (includes daily steroid doses in excess of 20 milligrams [mg]/day of prednisone).Xx_NEWLINE_xXActive treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisoneXx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day prednisoneXx_NEWLINE_xXGlucocorticoid therapy (prednisone > 30 mg/day or equivalent within 14 days of first dose)Xx_NEWLINE_xXTreatment with oral steroids (dose ? 10 mg/day of methylprednisolone or equivalent)Xx_NEWLINE_xXGlucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 14 days prior to randomizationXx_NEWLINE_xXRequirement, at time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray, or ophthalmic solutionXx_NEWLINE_xXPatients who are on chronic steroids for unrelated conditions (i.e. rheumatologic conditions) are not eligible if their total daily dose of steroids is equivalent to greater than 10 mg prednisoneXx_NEWLINE_xXReceiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent ? 5 mg prednisone or equivalent daily.Xx_NEWLINE_xXUse of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher within 6 weeks of day 1 of protocol therapyXx_NEWLINE_xXGlucocorticoid therapy (prednisone > 10 mg/day or equivalent) within the last three weeksXx_NEWLINE_xXNo history of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of 10 mg or less; NOTE: history of mild asthma not requiring daily therapy is eligibleXx_NEWLINE_xXConcomitant high dose corticosteroids (concurrent use of corticosteroids); EXCEPTION: patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for disorders other than amyloid, i.e., adrenal insufficiency, rheumatoid arthritis, etc.Xx_NEWLINE_xXLow-dose corticosteroids (prednisone <20 mg/ day or equivalent dose) are permitted throughout study.Xx_NEWLINE_xXHigh-dose corticosteroids (prednisone ?20mg/day or equivalent dose) must be discontinued ? 7 days of initiating therapy.Xx_NEWLINE_xXContraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir) and proton-pump inhibitor (e.g. lansoprazole). Corticosteroid therapy in a dose equivalent to dexamethasone ? 1.5 mg/day or prednisone ? 10 mg/day. (Steroid use is allowed if necessary to treat spinal cord compression and/or hypocalcaemia.)Xx_NEWLINE_xXSubject has received a cumulative dose of corticosteroids more than the equivalent of >= 140 mg of prednisone within the 2–week period before cycle 1, day 1Xx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are allowed while on protocol treatment; patients may be receiving stable doses of corticosteroids with a maximum dose of 10 mg of prednisone per day if they are being given for disorders other than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica or adrenal insufficiency, or asthmaXx_NEWLINE_xXOngoing corticosteroid use >30 mg per day prednisone or equivalent, for purposes other than lymphoma symptom controlXx_NEWLINE_xXPatients must be on a steroid dose less than or equal to 2 mg of dexamethasone daily (or equivalent), and this dose must not have increased for at least 14 days prior to obtaining the enrollment.Xx_NEWLINE_xXSystemic corticosteroid therapy > 2 mg of dexamethasone daily (or equivalent) at study enrollment.Xx_NEWLINE_xXChronic corticosteroid use equivalent to >= prednisone 10 mg dailyXx_NEWLINE_xXIf a patient is on corticosteroids, he/she must be on a non-escalating corticosteroid dose (not exceeding more than 16 mg daily of dexamethasone oral) for >= 5 daysXx_NEWLINE_xXDaily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate, or extracorporeal photopheresisXx_NEWLINE_xXNeed for chronic corticosteroid therapy of >=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic diseaseXx_NEWLINE_xXDoses ? 10 mg/day prednisolone or equivalent is allowed, provided that the steroid dose has been stable or tapering for at least 14 days prior to the first dose of CA-4948Xx_NEWLINE_xXImmunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810Xx_NEWLINE_xXGlucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 14 days prior to randomization.Xx_NEWLINE_xXCurrent chronic daily treatment with corticosteroids (>/= 10 mg/day methylprednisolone or equivalent), excluding inhaled steroidsXx_NEWLINE_xXActive autoimmune hemolytic anaemia (AIHA) and idiopathic thrombocytopenic purpura (ITP) requiring corticosteroid therapy greater than 25 mg prednisone (or equivalent) or chemotherapy.Xx_NEWLINE_xXGlucocorticoid use, unless given in doses less than or equal to 25mg/Day prednisone (or equivalent) for less than 7 Days for exacerbations other than CLL (e.g. asthma).*Xx_NEWLINE_xXSupraphysiologic doses of glucocorticoids (defined as > 30 mg of hydrocortisone per day or > 7.5 mg of Prednisone per day, or equivalent doses of other agents) or exposure to other immunosuppressive medications in the previous 30 days.Xx_NEWLINE_xXDaily requirement for corticosteroids (except for inhalational corticosteroids); prednisone =< 10mg/day or equivalent is permitted for other medical conditionsXx_NEWLINE_xXPatients may be on steroids prior to initiation of treatment as long as by cycle 1 day 1 steroids use was tapered down less than or equal to 20 mg of prednisoneXx_NEWLINE_xXOngoing corticosteroid use with > 10 mg of daily prednisone or equivalentXx_NEWLINE_xX=< grade 1 acute graft-versus-host disease (GVHD) at time of the CMV specific T cell infusion; patients with treated acute GVHD must be on a stable dose of therapy (no increase in immunosuppressive therapy for the 2 weeks before planned donor cell infusion); the dosage level of immunosuppressive therapy at the time of infusion should be no greater than 20 mg of prednisone daily or mycophenolate 1000 mg thrice daily (TID) or cyclosporine with a target level of 200 ng/ml or equivalentXx_NEWLINE_xXReceiving chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet functionXx_NEWLINE_xXtaking more than 8 mg of dexamethasone per dayXx_NEWLINE_xXCorticosteroid therapy at a dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomizationXx_NEWLINE_xXThe patient requires concomitant treatment with systemic corticosteroids or any other immunosuppressive agents. The use of prednisone, or equivalent, <0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids or topical steroids is permitted.Xx_NEWLINE_xXSystemic corticosteroid therapy > 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.Xx_NEWLINE_xXPatients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent)Xx_NEWLINE_xXRegular treatment with corticosteroids within the 4 weeks prior to the start of Cycle 1, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednisone/prednisoloneXx_NEWLINE_xXConcomitant high dose corticosteroids (concurrent use of corticosteroids) while on single agent ibrutinib; EXCEPTION: patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for disorders other than amyloid, (i.e., adrenal insufficiency, rheumatoid arthritis, etc)Xx_NEWLINE_xXReceipt of corticosteroids within 7 days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone or equivalent for at least 1 month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting, topical steroid use and inhaled steroids are permittedXx_NEWLINE_xXConcurrent systemic steroid therapy higher than physiologic dose (> 7.5 mg/day of prednisone)Xx_NEWLINE_xXPatients who are on high-dose steroids (doses > 10 mg/day of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > 10mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least 3 days prior to starting on the study drugsXx_NEWLINE_xXUse of any of the following medications within the past 6 months: testosterone, dehydroepiandrosterone (DHEA), estrogens, gonadotropin-releasing hormone (GnRH) analogs, antiandrogens, spironolactone, ketoconazole, recombinant human growth hormone (rhGH), megestrol acetate, prednisone 20 mg daily or equivalent doses of other glucocorticoids for more than two weeksXx_NEWLINE_xXUse of corticosteroids as defined by a daily dose of prednisone (or equivalent) of 5 mg or greater for more than 1 month continuously within 3 months of screeningXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with systemic corticosteroids (equivalent of > 10 mg/day of prednisone); patients may receive steroid therapy up to 10 days prior to starting ABVD to control lymphoma-related symptomsXx_NEWLINE_xXPatient must not have evidence of any clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease;\r\n* Concurrent opportunistic infection;\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollmentXx_NEWLINE_xXTreatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers are allowed.Xx_NEWLINE_xXSubjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per dayXx_NEWLINE_xXPre-existing condition that warrants long-term corticosteroid use greater than the equivalent of 10 mg prednisone daily; physiologic replacement is permitted; topical, intra-articular steroids or inhaled corticosteroids are permittedXx_NEWLINE_xXPrednisone equivalent of > 2m/kg for treatment of GVHD prior to administration of ibrutinibXx_NEWLINE_xXHigh dose steroid therapy (defined as > 5 mg prednisone, or equivalent, daily)Xx_NEWLINE_xXUncontrolled pain; if patient is on opioids for the treatment of cancer pain, he/she must have had no major dose change (> 25%) for at least 48 hours prior to study entry; the dose of morphine equivalent daily should not exceed 120 mg/day unless approved by the principal investigator (PI); change in opioid dose after study entry is allowedXx_NEWLINE_xXPatients with active, grade II-IV, acute graft versus (vs.) host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (> 0.5 mg/kg/day prednisone or its equivalent) as treatmentXx_NEWLINE_xXChronic GVHD that did not respond to high-dose corticosteroids (prednisone at 1.0 mg/kg/day for at least 1 week or prednisone at 0.5 mg/kg/day or 1 mg/kg every other day for at least 4 weeks), or second-line therapy (any)Xx_NEWLINE_xXPain score of at >= 5 on a scale of 0 – 10 within a week of enrollment OR pain score < 5 with >= 60 mg of morphine (or equivalent) per dayXx_NEWLINE_xXChronic opioid use as defined by use of more than 20 mg oxycodone, or equivalent, dailyXx_NEWLINE_xXSteroid-Refractory/Dependent aGVHD (ARM 2)\r\n* Pediatric or adult HCT recipient with grade II-IV steroid refractory or steroid-dependent acute GVHD, defined as any one of the following:\r\n** No response of acute GVHD after at least 4 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent\r\n** Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent\r\n** Failure to improve to at least grade II acute GVHD after 14 days of systemic corticosteroids, with initial doses of at least 2 mg/kg prednisone or equivalent\r\n** Flare of acute GVHD of at least grade II/IV severity while on steroids at a dose > 0.1/mg/kg/day; this can include late-onset aGVHD and overlap syndromeXx_NEWLINE_xXPatients receiving high dose opioids on a chronic basis (greater than or equivalent to 60 mg of morphine per day)Xx_NEWLINE_xXKnown history of chronic pain disorders and/or chronic opioid use defined as > 10 mg of oral (PO) morphine or equivalent used daily for at least 30 days prior to enrollmentXx_NEWLINE_xXPatients requiring high doses of glucocorticosteroids (>= 0.3 mg/kg prednisone or its equivalent)Xx_NEWLINE_xXFor patients on oral corticosteroids, they must be stable clinically on corticosteroids or tapered off prior to starting the study drug; for patients taking dexamethasone, the dose should not exceed 8 mg QD (or 4 mg twice daily [BID]), if clinically stable, and the dose should not be escalated over entry dose level, if clinically possible; the patient’s dose of dexamethasone will be evaluated by the principal investigator (PI), the patient’s study physician, and/or the study pharmacist on a case by case basis for safety; all doses of oral corticosteroids will be reduced by 50%, unless oral corticosteroids are at physiologic dose (e.g. dexamethasone 1 mg, prednisone 10 mg, or cortisone 30 mg); it is recommended that oral corticosteroid doses be escalated back to full dose on day 7 (2 days after aprepitant is discontinued)Xx_NEWLINE_xXOn strong opioids with morphine equivalent daily dose of 80-500 mg for at least one week, with stable (i.e. +/- 30%) regular dose over the last 24 hoursXx_NEWLINE_xXDexamethasone dose must be provided for treatment group assignment:\r\n* Group A: patients not on dexamethasone or on a dose =< 0.75 mg daily (or equivalent of an alternative corticosteroid)\r\n* Group B: patients who require dexamethasone >= 4 mg daily (or equivalent of an alternative corticosteroid)\r\n** Patients must have been on the group assignment dose of corticosteroids for at least 5 days prior to the dose of NT-I7; corticosteroid dose changes prior to the start of treatment are allowed as long as they do not alter patient’s group assignmentXx_NEWLINE_xXCorticosteroid use > 10 mg prednisone/dayXx_NEWLINE_xXSteroid dependent/refractory cGVHD defined as:\r\n* Steroid dependent disease: Persistent cGVHD manifestations requiring a glucocorticoid dose >= prednisone 0.25 mg/kg/day (0.5 mg/kg orally [po] every other day) for at least 12 weeks\r\n* Steroid refractory disease: Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednisone 0.5 mg/kg/day (1 mg/kg po every other day) for at least 4 weeksXx_NEWLINE_xXOn strong opioid intravenous continuous infusion morphine equivalent daily dose (MEDD) >= 70 mg/day at the time of enrollmentXx_NEWLINE_xXCancer patients with severe pain (i.e., >= 7 on NRS) already on opioid therapy for one week or longer, at least 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg of oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioidXx_NEWLINE_xXConcomitant immunosuppressive medications, such as methotrexate or TNF inhibitors, within 2 weeks of Study Day 0, exclusive of steroid doses ? 5 mg daily.Xx_NEWLINE_xXPatients using >= 20 mg/day of prednisone (or steroid equivalent dose) for any chronic medical conditionXx_NEWLINE_xXTreatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administrationXx_NEWLINE_xXSystemic steroid therapy or any immunosuppressive therapy (?10mg/day prednisone or equivalent).Xx_NEWLINE_xXConcurrent treatment with anti-Tumor necrosis factor alpha (TNF alpha) therapies, systemic corticosteroids (prednisone dose greater than [>]10 mg per day or equivalent) or other immune suppressive drugs within the 2 weeks prior to Screening. Steroids that are topical, inhaled, nasal (spray) or ophthalmic solution are permittedXx_NEWLINE_xXConcurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of > 20 mg/day of prednisone) within 28 days of the first dose of study drugXx_NEWLINE_xXIs receiving high dose corticosteroids (>10 mg prednisone daily or equivalent);Xx_NEWLINE_xXPatient requires more than 8 mg of dexamethasone daily or the equivalentXx_NEWLINE_xXPatient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day or prednisone or the equivalent; participants must be off of immunosuppressant therapy for at least 28 days prior to the first dose of the study drugXx_NEWLINE_xXPatients must have steroid refractory chronic (c) GVHD, defined as having persistent signs and symptoms of chronic GVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 2 weeks in the preceding 12 months (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms, or if not responding to any lines of therapy beyond steroids, or if the MD feels adding/increasing steroids would not be in the patient’s best interestXx_NEWLINE_xXOngoing prednisone requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXParticipants must have steroid-refractory chronic graft-versus-host disease (cGVHD); steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate glucocorticoids) without complete resolution of signs and symptoms; participants with either extensive chronic GVHD or limited chronic GVHD requiring systemic therapy are eligibleXx_NEWLINE_xXOngoing prednisone requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXOn strong opioids with morphine equivalent daily dose of 60-130 mg for at least one week, with stable (i.e. +/- 30%) regular dose over the last 24 hoursXx_NEWLINE_xXOn strong opioids with morphine equivalent daily dose of 80-500 mg, with stable (i.e. +/- 30%) regular dose over the last 24 hoursXx_NEWLINE_xXAcute GVHD must be corticosteroid refractory as defined by:\r\n* Progressive GVHD after at least 3 days on corticosteroids (>= 1 mg/kg of prednisone or equivalent); this means new organ involvement (skin, liver, or intestine) or increased organ specific symptoms sufficient to increase the organ stage by one or more\r\n* No improvement in GVHD after at least 7 days on corticosteroids (>= 1 mg/kg of prednisone or equivalent) OR insufficient improvement which warrants the addition of another systemic agent at the opinion of the treating investigator\r\n* GVHD during taper of corticosteroids which is unable to be tapered below 0.5 mg/kg/day of prednisone equivalent or, in the opinion of the treating physician, requires addition of another systemic agentXx_NEWLINE_xXMore than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days]).Xx_NEWLINE_xXPatients must have steroid refractory classic cutaneous, myofascial, or sclerodermatous cGVHD (+/- other organ involvement, clinically diagnosed), defined as having persistent signs and symptoms of chronic GVHD despite the use of prednisone at >= 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks in the preceding 12 months (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms or if not improving on any line of therapy beyond steroids or if treating physician feels that increasing or adding steroids is not in the patient’s best interests; note that the dose of systemic steroids can certainly be lower than 0.25 mg/kg/day at enrollmentXx_NEWLINE_xXOngoing prednisone requirement > 1 mg/kg/day (or equivalent)Xx_NEWLINE_xXPatients with a history of severe chronic pain on high dose narcotics (> 25 mg of oxycodone or equivalent daily) preceding diagnosis of cancerXx_NEWLINE_xXClinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day prednisoneXx_NEWLINE_xXPatients who have not shown a satisfactory response to methylprednisolone-equivalent doses at 2 mg/kg/day, based on adjusted body weightXx_NEWLINE_xXCurrent daily use of aspirin (> 81 mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen > 800 mg daily or equivalent)Xx_NEWLINE_xXChronic, current or recent (within the past 2 weeks) use of systemic steroid doses equivalent to prednisone > 5 mg daily for continued use > 14 days; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowedXx_NEWLINE_xXChronic use of steroids at immunosuppressive doses. (Note, physiologic replacement doses of glucocorticoid or mineralocorticoid are acceptable, eg. prednisone 5-10 mg/day; fludrocortisone 0.1-0.2 mg/day)Xx_NEWLINE_xXCurrent use of systemic corticosteroids at doses > 10mg/day prednisone or its equivalent; those receiving =< 10mg may be enrolled at discretion of investigatorXx_NEWLINE_xXPatients with steroid refractory chronic GVHD are defined as having persistent signs and symptoms of chronic GVHD despite the use of prednisone at >= 0.5 mg/kg/day for at least 2 weeks in the preceding 24 months (or equivalent doses of alternate corticosteroids) without complete resolution of signs and symptomsXx_NEWLINE_xXRequire, at the time of study entry, treatment with steroids > 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solutionXx_NEWLINE_xXAny condition requiring treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of the first dose of study drug; inhaled, topical, ocular or intra-articular corticosteroids and adrenal replacement steroid doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXOngoing treatment with corticosteroids with a dose >10 milligram (mg) prednisone or equivalent per day at the time of randomization; or >280 mg cumulative prednisone dose or equivalent for any 4-week period in the year prior to randomizationXx_NEWLINE_xXTreatment with systemic immune modulators including, but not limited to, nontopical systemic corticosteroids (unless the dose is ? 10 mg/day prednisone or equivalent), cyclosporine, and tacrolimus within 2 weeks before study day 1Xx_NEWLINE_xXChronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone greater than or equal to 20 mg/day, or equivalent. Inhaled and topical steroids are allowedXx_NEWLINE_xXPatients on established, chronic corticosteroid therapy (> 5 mg /day of prednisone or prednisone equivalent) prior to transplant; established, chronic corticosteroid therapy is defined as daily dosing of > 5 mg/day of prednisone or prednisone equivalent for at least 2 weeks prior to the start of conditioning/chemotherapy or plans to continue pre-transplant corticosteroids (> 5 mg/day of prednisone or prednisone equivalent) indefinitely after transplantationXx_NEWLINE_xXRequires immunosuppressive doses of corticosteroid therapy (> 10 mg/day prednisone equivalents) for >= 2 weeks prior to registrationXx_NEWLINE_xXSystemic steroids at physiologic doses (equivalent to dose of oral prednisone 10 mg) are permitted. Steroids as anti-emetics for chemotherapy are not allowed.Xx_NEWLINE_xXSubjects with a condition with anticipated use of systemic steroids above the equivalent of 10 mg prednisone are excluded.Xx_NEWLINE_xXRequire systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/d prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted. Subjects who have a history of adrenal insufficiency and are receiving greater than 10 mg/day systemic steroids may be eligible but only after Sponsor consultation.Xx_NEWLINE_xXCorticosteroids are allowed, but must be dosed at prednisone 20 mg (or equivalent) or lower prior to the start of chemotherapyXx_NEWLINE_xXUse of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollmentXx_NEWLINE_xXPrior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) > 450 mg/m²Xx_NEWLINE_xXTreatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers are allowed.Xx_NEWLINE_xX